<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INTRON A- interferon alfa-2b 
			 </strong><br><strong>INTRON A- interferon alfa-2b injection, solution </strong><br>Merck Sharp &amp; Dohme Corp.<br></p></div>
<h1>INTRON<span class="Sup">®</span> A <br> Interferon alfa-2b, <br> recombinant</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">For Injection</span></p>
<p><span class="Bold">PRODUCT INFORMATION</span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNING</span></h1>
<p class="First"><span class="Bold">Alpha interferons, including INTRON<span class="Sup">®</span> A, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.  Patients should be monitored closely with periodic clinical and laboratory evaluations.  Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy.  In many but not all cases these disorders resolve after stopping INTRON A therapy.  See <a href="#warnings">WARNINGS</a> and <a href="#adverse">ADVERSE REACTIONS</a>.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">INTRON<span class="Sup">®</span> A (Interferon alfa-2b) for intramuscular, subcutaneous, intralesional, or intravenous Injection is a purified sterile recombinant interferon product.</p>
<p>INTRON A recombinant for Injection has been classified as an alpha interferon and is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of <span class="Italics">Escherichia coli</span> bearing a genetically engineered plasmid containing an interferon alfa-2b gene from human leukocytes.  The fermentation is carried out in a defined nutrient medium containing the antibiotic tetracycline hydrochloride at a concentration of 5 to 10 mg/L; the presence of this antibiotic is not detectable in the final product. The specific activity of interferon alfa-2b, recombinant is approximately 2.6 × 10<span class="Sup">8</span> IU/mg protein as measured by the HPLC assay.</p>
<table width="75%">
<caption><span>Powder for Injection</span></caption>
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Vial Strength<br>Million IU</th>
<th class="Rrule" align="center">mL Diluent</th>
<th class="Rrule" align="center">Final Concentration after Reconstitution million IU/mL<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">mg INTRON A<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> per vial</th>
<th class="Rrule" align="center">Route of Administration</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Each mL also contains 20 mg glycine, 2.3 mg sodium phosphate dibasic, 0.55 mg sodium phosphate monobasic, and 1.0 mg human albumin.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Based on the specific activity of approximately 2.6 × 10<span class="Sup">8</span> IU/mg protein, as measured by HPLC assay.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0.038</td>
<td class="Rrule" align="center">IM, SC, IV, IL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">18</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">0.069</td>
<td class="Rrule" align="center">IM, SC, IV</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">50</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">50</td>
<td class="Rrule" align="center">0.192</td>
<td class="Rrule" align="center">IM, SC, IV</td>
</tr>
</tbody>
</table>
<p>Prior to administration, the INTRON A Powder for Injection is to be reconstituted with the provided Diluent for INTRON A (Sterile Water for Injection USP) (see <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>).  INTRON A Powder for Injection is a white to cream-colored powder.</p>
<table width="75%">
<caption><span>Solution Vials for Injection</span></caption>
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<col align="center" valign="bottom" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Vial Strength</th>
<th class="Rrule" align="center">Concentration<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</th>
<th class="Rrule" align="center">mg INTRON A<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a> per vial</th>
<th class="Rrule" align="center">Route of Administration</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Each mL contains 7.5 mg sodium chloride, 1.8 mg sodium phosphate dibasic, 1.3 mg sodium phosphate monobasic, 0.1 mg edetate disodium, 0.1 mg polysorbate 80, and 1.5 mg m-cresol as a preservative.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Based on the specific activity of approximately 2.6 × 10<span class="Sup">8</span> IU/mg protein as measured by HPLC assay.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>This is a multidose vial which contains a total of 22.8 million IU of interferon alfa-2b, recombinant per 3.8 mL in order to provide the delivery of six 0.5-mL doses, each containing 3 million IU of INTRON A (for a label strength of 18 million IU).</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">§</a></dt>
<dd>This is a multidose vial which contains a total of 32.0 million IU of interferon alfa-2b, recombinant per 3.2 mL in order to provide the delivery of five 0.5-mL doses, each containing 5 million IU of INTRON A (for a label strength of 25 million IU).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">18<a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a> MIU multidose</td>
<td class="Rrule" align="center">3 million IU/0.5 mL</td>
<td class="Rrule" align="center">0.088</td>
<td class="Rrule" align="center">IM, SC</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">25<a name="footnote-reference-6" href="#footnote-6" class="Sup">§</a> MIU multidose</td>
<td class="Rrule" align="center">5 million IU/0.5 mL</td>
<td class="Rrule" align="center">0.123</td>
<td class="Rrule" align="center">IM, SC, IL</td>
</tr>
</tbody>
</table>
<p>These packages do not require reconstitution prior to administration (see <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>). INTRON A Solution for Injection is a clear, colorless solution.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinpharm"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>General</h2>
<p class="First">The interferons are a family of naturally occurring small proteins and glycoproteins with molecular weights of approximately 15,000 to 27,600 daltons produced and secreted by cells in response to <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> and to synthetic or biological inducers.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Preclinical Pharmacology</h3>
<p class="First">Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface.  Once bound to the cell membrane, interferons initiate a complex sequence of intracellular events.  <span class="Italics">In vitro</span> studies demonstrated that these include the induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> for target cells, and inhibition of virus replication in virus-infected cells.</p>
<p>In a study using human <span class="product-label-link" type="condition" conceptid="4001172" conceptname="Hepatoblastoma">hepatoblastoma</span> cell line HB 611, the <span class="Italics">in vitro</span> antiviral activity of alpha interferon was demonstrated by its inhibition of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) replication.</p>
<p>The correlation between these <span class="Italics">in vitro</span> data and the clinical results is unknown.  Any of these activities might contribute to interferon's therapeutic effects.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1.2"></a><p></p>
<h3>Pharmacokinetics</h3>
<p class="First">The pharmacokinetics of INTRON<span class="Sup">®</span> A were studied in 12 healthy male volunteers following single doses of 5 million IU/m<span class="Sup">2</span> administered intramuscularly, subcutaneously, and as a 30-minute intravenous infusion in a crossover design.</p>
<p>The mean serum INTRON A concentrations following intramuscular and subcutaneous injections were comparable.  The maximum serum concentrations obtained via these routes were approximately 18 to 116 IU/mL and occurred 3 to 12 hours after administration.  The elimination half-life of INTRON A following both intramuscular and subcutaneous injections was approximately 2 to 3 hours.  Serum concentrations were undetectable by 16 hours after the injections.</p>
<p>After intravenous administration, serum INTRON A concentrations peaked (135-273 IU/mL) by the end of the 30-minute infusion, then declined at a slightly more rapid rate than after intramuscular or subcutaneous drug administration, becoming undetectable 4 hours after the infusion.  The elimination half-life was approximately 2 hours.</p>
<p>Urine INTRON A concentrations following a single dose (5 million IU/m<span class="Sup">2</span>) were not detectable after any of the parenteral routes of administration.  This result was expected since preliminary studies with isolated and perfused rabbit kidneys have shown that the kidney may be the main site of interferon catabolism.</p>
<p>There are no pharmacokinetic data available for the intralesional route of administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3"></a><p></p>
<h3>Serum Neutralizing Antibodies</h3>
<p class="First">In INTRON A-treated patients tested for antibody activity in clinical trials, serum anti-interferon neutralizing antibodies were detected in 0% (0/90) of patients with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span>, 0.8% (2/260) of patients treated intralesionally for condylomata acuminata, and 4% (1/24) of patients with AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span>. Serum neutralizing antibodies have been detected in less than 3% of patients treated with higher INTRON A doses in malignancies other than <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> or AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span>.  The clinical significance of the appearance of serum anti-interferon neutralizing activity in these indications is not known.</p>
<p>Serum anti-interferon neutralizing antibodies were detected in 7% (12/168) of patients either during treatment or after completing 12 to 48 weeks of treatment with 3 million IU TIW of INTRON A therapy for <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> and in 13% (6/48) of patients who received INTRON A therapy for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B at 5 million IU QD for 4 months, and in 3% (1/33) of patients treated at 10 million IU TIW.  Serum anti-interferon neutralizing antibodies were detected in 9% (5/53) of pediatric patients who received INTRON A therapy for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B at 6 million IU/m<span class="Sup">2</span> TIW.  Among all <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B or C patients, pediatrics and adults with detectable serum neutralizing antibodies, the titers detected were low (22/24 with titers less than or equal to 1:40 and 2/24 with titers less than or equal to 1:160).  The appearance of serum anti-interferon neutralizing activity did not appear to affect safety or efficacy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">Hairy Cell Leukemia</span></h2>
<p class="First">In clinical trials in patients with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span>, there was <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of hematopoiesis during the first 1 to 2 months of INTRON A treatment, resulting in reduced numbers of circulating red and white blood cells, and platelets.  Subsequently, both splenectomized and nonsplenectomized patients achieved substantial and sustained improvements in granulocytes, platelets, and hemoglobin levels in 75% of treated patients and at least some improvement (minor responses) occurred in 90%.  INTRON A treatment resulted in a decrease in bone marrow hypercellularity and hairy cell infiltrates.  The hairy cell index (HCI), which represents the percent of bone marrow cellularity times the percent of hairy cell infiltrate, was greater than or equal to 50% at the beginning of the study in 87% of patients.  The percentage of patients with such an HCI decreased to 25% after 6 months and to 14% after 1 year.  These results indicate that even though hematologic improvement had occurred earlier, prolonged INTRON A treatment may be required to obtain maximal reduction in tumor cell infiltrates in the bone marrow.</p>
<p>The percentage of patients with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> who required red blood cell or platelet transfusions decreased significantly during treatment and the percentage of patients with confirmed and serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> declined as granulocyte counts improved.  Reversal of <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span> and of clinically significant <span class="product-label-link" type="condition" conceptid="192298" conceptname="Hypersplenism">hypersplenism</span> was demonstrated in some patients.</p>
<p>A study was conducted to assess the effects of extended INTRON A treatment on duration of response for patients who responded to initial therapy.  In this study, 126 responding patients were randomized to receive additional INTRON A treatment for 6 months or observation for a comparable period, after 12 months of initial INTRON A therapy.  During this 6-month period, 3% (2/66) of INTRON A-treated patients relapsed compared with 18% (11/60) who were not treated.  This represents a significant difference in time to relapse in favor of continued INTRON A treatment (<span class="Italics">P</span>=0.006/0.01, Log Rank/Wilcoxon).  Since a small proportion of the total population had relapsed, median time to relapse could not be estimated in either group.  A similar pattern in relapses was seen when all randomized treatment, including that beyond 6 months, and available follow-up data were assessed.  The 15% (10/66) relapses among INTRON A patients occurred over a significantly longer period of time than the 40% (24/60) with observation (<span class="Italics">P</span>=0.0002/0.0001, Log Rank/Wilcoxon).  Median time to relapse was estimated, using the Kaplan-Meier method, to be 6.8 months in the observation group but could not be estimated in the INTRON A group.</p>
<p>Subsequent follow-up with a median time of approximately 40 months demonstrated an overall survival of 87.8%.  In a comparable historical control group followed for 24 months, overall median survival was approximately 40%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Malignant Melanoma</h2>
<p class="First">The safety and efficacy of INTRON A was evaluated as adjuvant to surgical treatment in patients with melanoma who were free of disease (post surgery) but at high risk for systemic recurrence.  These included patients with lesions of Breslow thickness greater than 4 mm, or patients with lesions of any Breslow thickness with primary or recurrent nodal involvement.  In a randomized, controlled trial in 280 patients, 143 patients received INTRON A therapy at 20 million IU/m<span class="Sup">2</span> intravenously five times per week for 4 weeks (induction phase) followed by 10 million IU/m<span class="Sup">2</span> subcutaneously three times per week for 48 weeks (maintenance phase).  In the clinical trial, the median daily INTRON A dose administered to patients was 19.1 million IU/m<span class="Sup">2</span> during the induction phase and 9.1 million IU/m<span class="Sup">2</span> during the maintenance phase.  INTRON A therapy was begun less than or equal to 56 days after surgical resection.  The remaining 137 patients were observed.</p>
<p>INTRON A therapy produced a significant increase in relapse-free and overall survival.  Median time to relapse for the INTRON A-treated patients versus observation patients was 1.72 years versus 0.98 years (<span class="Italics">P</span>&lt;0.01, stratified Log Rank).  The estimated 5-year relapse-free survival rate, using the Kaplan-Meier method, was 37% for INTRON A-treated patients versus 26% for observation patients.  Median overall survival time for INTRON A-treated patients versus observation patients was 3.82 years versus 2.78 years (<span class="Italics">P</span>=0.047, stratified Log Rank).  The estimated 5-year overall survival rate, using the Kaplan-Meier method, was 46% for INTRON A-treated patients versus 37% for observation patients.</p>
<p>In a second study of 642 resected high-risk melanoma patients, subjects were randomized equally to one of three groups: high-dose INTRON A therapy for 1 year (same schedule as above), low-dose INTRON A therapy for 2 years (3 MU/d TIW SC), and observation.  Consistent with the earlier trial, high-dose INTRON A therapy demonstrated an improvement in relapse-free survival (3-year estimated RFS 48% versus 41%; median RFS 2.4 versus 1.6 years, <span class="Italics">P</span>=not significant).  Relapse-free survival in the low-dose INTRON A arm was similar to that seen in the observation arm.  Neither high-dose nor low-dose INTRON A therapy showed a benefit in overall survival as compared to observation in this study.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">The safety and efficacy of INTRON A in conjunction with CHVP, a combination chemotherapy regimen, was evaluated as initial treatment in patients with clinically aggressive, large tumor burden, Stage III/IV follicular Non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span>.  Large tumor burden was defined by the presence of any one of the following:  a nodal or extranodal tumor <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> with a diameter of greater than 7 cm; involvement of at least three nodal sites (each with a diameter of greater than 3 cm); systemic symptoms; <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>; serous <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span>, orbital or epidural involvement; ureteral compression; or <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>.</p>
<p>In a randomized, controlled trial, 130 patients received CHVP therapy and 135 patients received CHVP therapy plus INTRON A therapy at 5 million IU subcutaneously three times weekly for the duration of 18 months.  CHVP chemotherapy consisted of cyclophosphamide 600 mg/m<span class="Sup">2</span>, doxorubicin 25 mg/m<span class="Sup">2</span>, and teniposide (VM-26) 60 mg/m<span class="Sup">2</span>, administered intravenously on Day 1 and prednisone at a daily dose of 40 mg/m<span class="Sup">2</span> given orally on Days 1 to 5.  Treatment consisted of six CHVP cycles administered monthly, followed by an additional six cycles administered every 2 months for 1 year.  Patients in both treatment groups received a total of 12 CHVP cycles over 18 months.</p>
<p>The group receiving the combination of INTRON A therapy plus CHVP had a significantly longer progression-free survival (2.9 years versus 1.5 years, <span class="Italics">P</span>=0.0001, Log Rank test).  After a median follow-up of 6.1 years, the median survival for patients treated with CHVP alone was 5.5 years while median survival for patients treated with CHVP plus INTRON A therapy had not been reached (<span class="Italics">P</span>=0.004, Log Rank test).  In three additional published, randomized, controlled studies of the addition of interferon alpha to anthracycline-containing combination chemotherapy regimens,<span class="Sup">1-3</span> the addition of interferon alpha was associated with significantly prolonged progression-free survival.  Differences in overall survival were not consistently observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5"></a><p></p>
<h2>Condylomata Acuminata</h2>
<p class="First">Condylomata acuminata (venereal or <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>) are associated with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the human <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> virus (HPV).  The safety and efficacy of INTRON A in the treatment of condylomata acuminata were evaluated in three controlled double-blind clinical trials.  In these studies, INTRON A doses of 1 million IU per lesion were administered intralesionally three times a week (TIW), in less than or equal to 5 lesions per patient for 3 weeks.  The patients were observed for up to 16 weeks after completion of the full treatment course.</p>
<p>INTRON A treatment of condylomata was significantly more effective than placebo, as measured by disappearance of lesions, decreases in lesion size, and by an overall change in disease status.  Of 192 INTRON A-treated patients and 206 placebo-treated patients who were evaluable for efficacy at the time of best response during the course of the study, 42% of INTRON A patients versus 17% of placebo patients experienced clearing of all treated lesions.  Likewise, 24% of INTRON A patients versus 8% of placebo patients experienced marked (75% to less than 100%) reduction in lesion size, 18% versus 9% experienced moderate (50% to 75%) reduction in lesion size, 10% versus 42% had a slight (less than 50%) reduction in lesion size, 5% versus 24% had no change in lesion size, and 0% versus 1% experienced exacerbation (<span class="Italics">P</span>&lt;0.001).</p>
<p>In one of these studies, 43% (54/125) of patients in whom multiple (less than or equal to 3) lesions were treated experienced complete clearing of all treated lesions during the course of the study. Of these patients, 81% remained cleared 16 weeks after treatment was initiated.</p>
<p>Patients who did not achieve total clearing of all their treated lesions had these same lesions treated with a second course of therapy.  During this second course of treatment, 38% to 67% of patients had clearing of all treated lesions.  The overall percentage of patients who had cleared all their treated lesions after two courses of treatment ranged from 57% to 85%.</p>
<p>INTRON A-treated lesions showed improvement within 2 to 4 weeks after the start of treatment in the above study; maximal response to INTRON A therapy was noted 4 to 8 weeks after initiation of treatment.</p>
<p>The response to INTRON A therapy was better in patients who had condylomata for shorter durations than in patients with lesions for a longer duration.</p>
<p>Another study involved 97 patients in whom three lesions were treated with either an intralesional injection of 1.5 million IU of INTRON A per lesion followed by a topical application of 25% podophyllin, or a topical application of 25% podophyllin alone.  Treatment was given once a week for 3 weeks.  The combined treatment of INTRON A and podophyllin was shown to be significantly more effective than podophyllin alone, as determined by the number of patients whose lesions cleared.  This significant difference in response was evident after the second treatment (Week 3) and continued through 8 weeks post-treatment.  At the time of the patient's best response, 67% (33/49) of the INTRON A- and podophyllin-treated patients had all three treated lesions clear while 42% (20/48) of the podophyllin-treated patients had all three clear (<span class="Italics">P</span>=0.003).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6"></a><p></p>
<h2>AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span></h2>
<p class="First">The safety and efficacy of INTRON A in the treatment of Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span> (KS), a common manifestation of the <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immune Deficiency Syndrome</span> (AIDS), were evaluated in clinical trials in 144 patients.</p>
<p>In one study, INTRON A doses of 30 million IU/m<span class="Sup">2</span> were administered subcutaneously three times per week (TIW) to patients with AIDS-Related KS.  Doses were adjusted for patient tolerance.  The average weekly dose delivered in the first 4 weeks was 150 million IU; at the end of 12 weeks this averaged 110 million IU/week; and by 24 weeks averaged 75 million IU/week.</p>
<p>Forty-four percent of asymptomatic patients responded versus 7% of symptomatic patients.  The median time to response was approximately 2 months and 1 month, respectively, for asymptomatic and symptomatic patients.  The median duration of response was approximately 3 months and 1 month, respectively, for the asymptomatic and symptomatic patients.  Baseline T4/T8 ratios were 0.46 for responders versus 0.33 for nonresponders.</p>
<p>In another study, INTRON A doses of 35 million IU were administered subcutaneously, daily (QD), for 12 weeks. Maintenance treatment, with every other day dosing (QOD), was continued for up to 1 year in patients achieving antitumor and antiviral responses.  The median time to response was 2 months and the median duration of response was 5 months in the asymptomatic patients.</p>
<p>In all studies, the likelihood of response was greatest in patients with relatively intact immune systems as assessed by baseline CD4 counts (interchangeable with T4 counts).  Results at doses of 30 million IU/m<span class="Sup">2</span> TIW and 35 million IU/QD were subcutaneously similar and are provided together in TABLE 1. This table demonstrates the relationship of response to baseline CD4 count in both asymptomatic and symptomatic patients in the 30 million IU/m<span class="Sup">2</span> TIW and the 35 million IU/QD treatment groups.</p>
<p>In the 30 million IU study group, 7% (5/72) of patients were complete responders and 22% (16/72) of the patients were partial responders.  The 35 million IU study had 13% (3/23 patients) complete responders and 17% (4/23) partial responders.</p>
<p>For patients who received 30 million IU TIW, the median survival time was longer in patients with CD4 greater than 200 (30.7 months) than in patients with CD4 less than or equal to 200 (8.9 months).  Among responders, the median survival time was 22.6 months versus 9.7 months in nonresponders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CP_Chronic_Hepatitis_C"></a><a name="section-3.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span></h2>
<p class="First">The safety and efficacy of INTRON A in the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> was evaluated in 5 randomized clinical studies in which an INTRON A dose of 3 million IU three times a week (TIW) was assessed.  The initial three studies were placebo-controlled trials that evaluated a 6-month (24-week) course of therapy.  In each of the three studies, INTRON A therapy resulted in a reduction in serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) in a greater proportion of patients versus control patients at the end of 6 months of dosing.  During the 6 months of follow-up, approximately 50% of the patients who responded maintained their ALT response.  A combined analysis comparing pretreatment and post-treatment liver biopsies revealed histological improvement in a statistically significantly greater proportion of INTRON A-treated patients compared to controls.</p>
<p>Two additional studies have investigated longer treatment durations (up to 24 months).<span class="Sup">5,6</span>  Patients in the two studies to evaluate longer duration of treatment had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with or without cirrhosis in the absence of decompensated liver disease.  Complete response to treatment was defined as normalization of the final two serum ALT levels during the treatment period. A sustained response was defined as a complete response at the end of the treatment period, with sustained normal ALT values lasting at least 6 months following discontinuation of therapy.</p>
<p>In Study 1, all patients were initially treated with INTRON A 3 million IU TIW subcutaneously for 24 weeks (run-in-period).  Patients who completed the initial 24-week treatment period were then randomly assigned to receive no further treatment, or to receive 3 million IU TIW for an additional 48 weeks.  In Study 2, patients who met the entry criteria were randomly assigned to receive INTRON A 3 million IU TIW subcutaneously for 24 weeks or to receive INTRON A 3 million IU TIW subcutaneously for 96 weeks.  In both studies, patient follow-up was variable and some data collection was retrospective.</p>
<p>Results show that longer durations of INTRON A therapy improved the sustained response rate (see <a href="#table2">TABLE 2</a>).  In patients with complete responses (CR) to INTRON A therapy after 6 months of treatment (149/352 [42%]), responses were less often sustained if drug was discontinued (21/70 [30%]) than if it was continued for 18 to 24 months (44/79 [56%]).  Of all patients randomized, the sustained response rate in the patients receiving 18 or 24 months of therapy was 22% and 26%, respectively, in the two trials.  In patients who did not have a CR by 6 months, additional therapy did not result in significantly more responses, since almost all patients who responded to therapy did so within the first 16 weeks of treatment.</p>
<p>A subset (less than 50%) of patients from the combined extended dosing studies had liver biopsies performed both before and after INTRON A treatment.  Improvement in necroinflammatory activity as assessed retrospectively by the Knodell (Study 1) and Scheuer (Study 2) Histology Activity Indices was observed in both studies.  A higher number of patients (58%, 45/78) improved with extended therapy than with shorter (6 months) therapy (38%, 34/89) in this subset.</p>
<p>Combination treatment with INTRON A and REBETOL<span class="Sup">®</span> (ribavirin USP) provided a significant reduction in virologic load and improved histologic response in adult patients with compensated liver disease who were treatment-naïve or had relapsed following therapy with alpha interferon alone; pediatric patients previously untreated with alpha interferon experienced a sustained virologic response. See REBETOL prescribing information for additional information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.8.1"></a><p></p>
<h3>Adults</h3>
<p class="First">The safety and efficacy of INTRON A in the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B were evaluated in three clinical trials in which INTRON A doses of 30 to 35 million IU per week were administered subcutaneously (SC), as either 5 million IU daily (QD), or 10 million IU three times a week (TIW) for 16 weeks versus no treatment.  All patients were 18 years of age or older with compensated liver disease, and had <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (serum HBsAg positive for at least 6 months) and HBV replication (serum HBeAg positive).  Patients were also serum HBV-DNA positive, an additional indicator of HBV replication, as measured by a research assay.<span class="Sup">7,8</span> All patients had elevated serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) and liver biopsy findings compatible with the diagnosis of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span>.  Patients with the presence of antibody to human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (anti-HIV) or antibody to <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> delta virus (anti-HDV) in the serum were excluded from the studies.</p>
<p>Virologic response to treatment was defined in these studies as a loss of serum markers of HBV replication (HBeAg and HBV DNA).  Secondary parameters of response included loss of serum HBsAg, decreases in serum ALT, and improvement in liver histology.</p>
<p>In each of two randomized controlled studies, a significantly greater proportion of INTRON A-treated patients exhibited a virologic response compared with untreated control patients (see <a href="#table3">TABLE 3</a>).  In a third study without a concurrent control group, a similar response rate to INTRON A therapy was observed.  Pretreatment with prednisone, evaluated in two of the studies, did not improve the response rate and provided no additional benefit.</p>
<p>The response to INTRON A therapy was durable. No patient responding to INTRON A therapy at a dose of 5 million IU QD or 10 million IU TIW relapsed during the follow-up period, which ranged from 2 to 6 months after treatment ended.  The loss of serum HBeAg and HBV DNA was maintained in 100% of 19 responding patients followed for 3.5 to 36 months after the end of therapy.</p>
<p>In a proportion of responding patients, loss of HBeAg was followed by the loss of HBsAg.  HBsAg was lost in 27% (4/15) of patients who responded to INTRON A therapy at a dose of 5 million IU QD, and 35% (8/23) of patients who responded to 10 million IU TIW.  No untreated control patient lost HBsAg in these studies.</p>
<p>In an ongoing study to assess the long-term durability of virologic response, 64 patients responding to INTRON A therapy have been followed for 1.1 to 6.6 years after treatment; 95% (61/64) remain serum HBeAg negative, and 49% (30/61) lost serum HBsAg.</p>
<p>INTRON A therapy resulted in normalization of serum ALT in a significantly greater proportion of treated patients compared to untreated patients in each of two controlled studies (see <a href="#table4">TABLE 4</a>).  In a third study without a concurrent control group, normalization of serum ALT was observed in 50% (12/24) of patients receiving INTRON A therapy.</p>
<p>Virologic response was associated with a reduction in serum ALT to normal or near normal (less than or equal to 1.5 × the upper limit of normal) in 87% (13/15) of patients responding to INTRON A therapy at 5 million IU QD, and 100% (23/23) of patients responding to 10 million IU TIW.</p>
<p>Improvement in liver histology was evaluated in Studies 1 and 3 by comparison of pretreatment and 6-month post-treatment liver biopsies using the semiquantitative Knodell Histology Activity Index.<span class="Sup">9</span> No statistically significant difference in liver histology was observed in treated patients compared to control patients in Study 1.  Although statistically significant histological improvement from baseline was observed in treated patients in Study 3 (<span class="Italics">P</span>≤0.01), there was no control group for comparison.  Of those patients exhibiting a virologic response following treatment with 5 million IU QD or 10 million IU TIW, histological improvement was observed in 85% (17/20) compared to 36% (9/25) of patients who were not virologic responders.  The histological improvement was due primarily to decreases in severity of <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, degeneration, and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in the periportal, lobular, and portal regions of the liver (Knodell Categories I + II + III).  Continued histological improvement was observed in four responding patients who lost serum HBsAg and were followed 2 to 4 years after the end of INTRON A therapy.<span class="Sup">10</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.8.2"></a><p></p>
<h3>Pediatrics</h3>
<p class="First">The safety and efficacy of INTRON A in the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B was evaluated in one randomized controlled trial of 149 patients ranging from 1 year to 17 years of age.  Seventy-two patients were treated with 3 million IU/m<span class="Sup">2</span> of INTRON A therapy administered subcutaneously three times a week (TIW) for 1 week; the dose was then escalated to 6 million IU/m<span class="Sup">2</span> TIW for a minimum of 16 weeks up to 24 weeks.  The maximum weekly dosage was 10 million IU TIW.  Seventy-seven patients were untreated controls.  Study entry and response criteria were identical to those described in the adult patient population.</p>
<p>Patients treated with INTRON A therapy had a better response (loss of HBV DNA and HBeAg at 24 weeks of follow-up) compared to the untreated controls (24% [17/72] versus 10% [8/77] <span class="Italics">P</span>=0.05).  Sixteen of the 17 responders treated with INTRON A therapy remained HBV DNA and HBeAg negative and had a normal serum ALT 12 to 24 months after completion of treatment.  Serum HBsAg became negative in 7 out of 17 patients who responded to INTRON A therapy.  None of the control patients who had an HBV DNA and HBeAg response became HBsAg negative.  At 24 weeks of follow-up, normalization of serum ALT was similar in patients treated with INTRON A therapy (17%, 12/72) and in untreated control patients (16%, 12/77).  Patients with a baseline HBV DNA less than 100 pg/mL were more likely to respond to INTRON A therapy than were patients with a baseline HBV DNA greater than 100 pg/mL (35% versus 9%, respectively).  Patients who contracted <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B through maternal vertical transmission had lower response rates than those who contracted the disease by other means (5% versus 31%, respectively).  There was no evidence that the effects on HBV DNA and HBeAg were limited to specific subpopulations based on age, gender, or race.</p>
<a name="table1"></a><table width="75%">
<caption><span>TABLE 1 RESPONSE BY BASELINE CD4 COUNT<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a> IN AIDS-RELATED KS PATIENTS</span></caption>
<col align="left" valign="top" width="26%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="5"><span class="Italics Underline">30 million IU/m<span class="Sup">2</span> TIW, SC and 35 million IU QD, SC</span></th>
</tr>
<tr class="Last">
<th align="left"></th>
<th class="Botrule" align="center" colspan="2"><span class="Italics">Asymptomatic</span></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="2"><span class="Italics">Symptomatic</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Data for CD4, and asymptomatic and symptomatic classification were not available for all patients.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">CD4&lt;200</td>
<td align="center">4/14</td>
<td align="center">(29%)</td>
<td align="center"></td>
<td align="center">0/19</td>
<td align="center">(0%)</td>
</tr>
<tr>
<td align="left">200≤CD4≤400</td>
<td align="center">6/12</td>
<td align="center">(50%)</td>
<td align="center"></td>
<td align="center">0/5</td>
<td align="center">(0%)</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">} 58%</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">CD4&gt;400</td>
<td align="center">5/7</td>
<td align="center">(71%)</td>
<td align="center"></td>
<td align="center">0/0</td>
<td align="center">(0%)</td>
</tr>
</tbody>
</table>
<a name="table2"></a><table width="75%">
<caption><span>TABLE 2 SUSTAINED ALT RESPONSE RATE VERSUS DURATION OF THERAPY IN <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">CHRONIC HEPATITIS C</span> PATIENTS INTRON A 3 Million IU TIW</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th align="center"></th>
<th align="center" colspan="3"><span class="Italics Underline">Treatment Group<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a> - Number of Patients (%)</span></th>
</tr>
<tr class="Last">
<th align="center"><span class="Italics">Study Number</span></th>
<th align="center"><span class="Italics">INTRON A 3 million IU 24 weeks of treatment</span></th>
<th align="center">
<span class="Italics">INTRON A 3 million IU 72 or 96 weeks of treatment</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a>
</th>
<th align="center">
<span class="Italics">Difference (Extended — 24 weeks)<br>(95% CI)</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">‡</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Intent-to-treat groups.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>Study 1: 72 weeks of treatment; Study 2: 96 weeks of treatment.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">‡</a></dt>
<dd>Confidence intervals adjusted for multiple comparisons due to 3 treatment arms in the study.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td align="center" colspan="4"><span class="Bold">ALT response at the end of follow-up</span></td></tr>
<tr>
<td align="center">1</td>
<td align="center">12/101 (12%)</td>
<td align="center">23/104 (22%)</td>
<td align="center">10% (-3, 24)</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">9/67 (13%)</td>
<td align="center">21/80 (26%)</td>
<td align="center">13% (-4, 30)</td>
</tr>
<tr class="Botrule">
<td align="center"><span class="Bold">Combined Studies</span></td>
<td align="center"><span class="Bold">21/168 (12.5%)</span></td>
<td align="center"><span class="Bold">44/184 (24%)</span></td>
<td align="center"><span class="Bold">11.4% (2, 21)</span></td>
</tr>
<tr><td align="center" colspan="4"><span class="Bold">ALT response at the end of treatment</span></td></tr>
<tr>
<td align="center">1</td>
<td align="center">40/101 (40%)</td>
<td align="center">51/104 (49%)</td>
<td align="center">--</td>
</tr>
<tr class="Last">
<td align="center">2</td>
<td align="center">32/67 (48%)</td>
<td align="center">35/80 (44%)</td>
<td align="center">--</td>
</tr>
</tbody>
</table>
<a name="table3"></a><table width="75%">
<caption><span>TABLE 3 VIROLOGIC RESPONSE<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a> IN <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">CHRONIC HEPATITIS</span> B PATIENTS</span></caption>
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th align="center"></th>
<th align="center" colspan="6"><span class="Italics Underline">Treatment Group<a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a> - Number of Patients (%)</span></th>
<th align="center"></th>
</tr>
<tr class="Last">
<th align="center"><span class="Italics">Study Number</span></th>
<th align="center" colspan="2"><span class="Italics">INTRON A 5 million IU QD</span></th>
<th align="center" colspan="2"><span class="Italics">INTRON A 10 million IU TIW</span></th>
<th align="center" colspan="2"><span class="Italics">Untreated Controls</span></th>
<th align="center"><span class="Italics">P<a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a> Value</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Loss of HBeAg and HBV DNA by 6 months post-therapy.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Patients pretreated with prednisone not shown.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd>INTRON A treatment group versus untreated control.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">§</a></dt>
<dd>Untreated control patients evaluated after 24-week observation period.  A subgroup subsequently received INTRON A therapy.  A direct comparison is not applicable (NA).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center">1<span class="Sup">7</span>
</td>
<td align="center">15/38</td>
<td align="center">(39%)</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">3/42</td>
<td align="center">(7%)</td>
<td align="center">0.0009</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">10/24</td>
<td align="center">(42%)</td>
<td align="center">1/22</td>
<td align="center">(5%)</td>
<td align="center">0.005</td>
</tr>
<tr class="Botrule">
<td align="center">3<span class="Sup">8</span>
</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">13/24<a name="footnote-reference-14" href="#footnote-14" class="Sup">§</a>
</td>
<td align="center">(54%)</td>
<td align="center">2/27</td>
<td align="center">(7%)<a href="#footnote-14" class="Sup">§</a>
</td>
<td align="center">NA<a href="#footnote-14" class="Sup">§</a>
</td>
</tr>
<tr class="Last">
<td align="center"><span class="Bold">All Studies</span></td>
<td align="center"><span class="Bold">15/38</span></td>
<td align="center"><span class="Bold">(39%)</span></td>
<td align="center"><span class="Bold">23/48</span></td>
<td align="center"><span class="Bold">(48%)</span></td>
<td align="center"><span class="Bold">6/91</span></td>
<td align="center"><span class="Bold">(7%)</span></td>
<td align="center"><span class="Bold">--</span></td>
</tr>
</tbody>
</table>
<a name="table4"></a><table width="75%">
<caption><span>TABLE 4 ALT RESPONSES<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a> IN <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">CHRONIC HEPATITIS</span> B PATIENTS</span></caption>
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th align="center"></th>
<th align="center" colspan="6"><span class="Italics Underline">Treatment Group - Number of Patients (%)</span></th>
<th align="center"></th>
</tr>
<tr class="Last">
<th align="center"><span class="Italics">Study Number</span></th>
<th align="center" colspan="2"><span class="Italics">INTRON A 5 million IU QD</span></th>
<th align="center" colspan="2"><span class="Italics">INTRON A 10 million IU TIW</span></th>
<th align="center" colspan="2"><span class="Italics">Untreated Controls</span></th>
<th align="center"><span class="Italics">P<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a> Value</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Reduction in serum ALT to normal by 6 months post-therapy.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>INTRON A treatment group versus untreated control.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>Untreated control patients evaluated after 24-week observation period.  A subgroup subsequently received INTRON A therapy.  A direct comparison is not applicable (NA).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center">1</td>
<td align="center">16/38</td>
<td align="center">(42%)</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">8/42</td>
<td align="center">(19%)</td>
<td align="center">0.03</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">10/24</td>
<td align="center">(42%)</td>
<td align="center">1/22</td>
<td align="center">(5%)</td>
<td align="center">0.0034</td>
</tr>
<tr class="Botrule">
<td align="center">3</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">12/24<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a>
</td>
<td align="center">(50%)</td>
<td align="center">2/27</td>
<td align="center">(7%)<a href="#footnote-17" class="Sup">‡</a>
</td>
<td align="center">NA<a href="#footnote-17" class="Sup">‡</a>
</td>
</tr>
<tr class="Last">
<td align="center"><span class="Bold">All Studies</span></td>
<td align="center"><span class="Bold">16/38</span></td>
<td align="center"><span class="Bold">(42%)</span></td>
<td align="center"><span class="Bold">22/48</span></td>
<td align="center"><span class="Bold">(46%)</span></td>
<td align="center"><span class="Bold">11/91</span></td>
<td align="center"><span class="Bold">(12%)</span></td>
<td align="center"><span class="Bold">--</span></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="indications"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">Hairy Cell Leukemia</span></h2>
<p class="First">INTRON<span class="Sup">®</span> A is indicated for the treatment of patients 18 years of age or older with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Malignant Melanoma</h2>
<p class="First">INTRON A is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2>Follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">INTRON A is indicated for the initial treatment of clinically aggressive (see <span class="Bold"><a href="#clinpharm">Clinical Pharmacology</a></span>) follicular Non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older.  Efficacy of INTRON A therapy in patients with low-grade, low-tumor burden follicular Non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> has not been demonstrated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2>Condylomata Acuminata</h2>
<p class="First">INTRON A is indicated for intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas (see <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>The use of this product in adolescents has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.5"></a><p></p>
<h2>AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span></h2>
<p class="First">INTRON A is indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span>.  The likelihood of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span> and who have a relatively intact immune system as indicated by total CD4 count.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span></h2>
<p class="First">INTRON A is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive. Studies in these patients demonstrated that INTRON A therapy can produce clinically meaningful effects on this disease, manifested by normalization of serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) and reduction in <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and degeneration.</p>
<p>A liver biopsy should be performed to establish the diagnosis of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span>.  Patients should be tested for the presence of antibody to HCV. Patients with other causes of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span>, including <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span>, should be excluded.  Prior to initiation of INTRON A therapy, the physician should establish that the patient has compensated liver disease. The following patient entrance criteria for compensated liver disease were used in the clinical studies and should be considered before INTRON A treatment of patients with <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>:</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless">
<tr><td align="left" colspan="2"><ul class="Disc"><li>No history of <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, variceal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, or other clinical signs of decompensation</li></ul></td></tr>
<tr>
<td align="left"><ul class="Disc"><li>Bilirubin</li></ul></td>
<td align="left">Less than or equal to 2 mg/dL</td>
</tr>
<tr>
<td align="left"><ul class="Disc"><li>Albumin </li></ul></td>
<td align="left">Stable and within normal limits</td>
</tr>
<tr>
<td align="left"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> Time </li></ul></td>
<td align="left">Less than 3 seconds prolonged</td>
</tr>
<tr>
<td align="left"><ul class="Disc"><li>WBC</li></ul></td>
<td align="left">Greater than or equal to 3000/mm<span class="Sup">3</span>
</td>
</tr>
<tr>
<td align="left"><ul class="Disc"><li>Platelets</li></ul></td>
<td align="left">Greater than or equal to 70,000/mm<span class="Sup">3</span>
</td>
</tr>
</tbody>
</table>
<p>Serum creatinine should be normal or near normal.</p>
<p>Prior to initiation of INTRON A therapy, CBC and platelet counts should be evaluated in order to establish baselines for monitoring potential toxicity. These tests should be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, and monthly thereafter. Serum ALT should be evaluated at approximately 3-month intervals to assess response to treatment (see <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>Patients with preexisting thyroid abnormalities may be treated if thyroid-stimulating hormone (TSH) levels can be maintained in the normal range by medication.  TSH levels must be within normal limits upon initiation of INTRON A treatment and TSH testing should be repeated at 3 and 6 months (see <span class="Bold"><a href="#labtest">PRECAUTIONS, Laboratory Tests</a></span>).</p>
<p>INTRON A in combination with REBETOL<span class="Sup">®</span> is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> in patients 3 years of age and older with compensated liver disease previously untreated with alpha interferon therapy and in patients 18 years of age and older who have relapsed following alpha interferon therapy.  See REBETOL prescribing information for additional information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</h2>
<p class="First">INTRON A is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B in patients 1 year of age or older with compensated liver disease.  Patients who have been serum HBsAg positive for at least 6 months and have evidence of HBV replication (serum HBeAg positive) with elevated serum ALT are candidates for treatment.  Studies in these patients demonstrated that INTRON A therapy can produce virologic remission of this disease (loss of serum HBeAg) and normalization of serum aminotransferases. INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.</p>
<p>Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy be performed to establish the presence of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> and the extent of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>.  The physician should establish that the patient has compensated liver disease.  The following patient entrance criteria for compensated liver disease were used in the clinical studies and should be considered before INTRON A treatment of patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B:</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless">
<tr><td align="left" colspan="2"><ul class="Disc"><li>No history of <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, variceal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, or other signs of clinical decompensation</li></ul></td></tr>
<tr>
<td align="left"><ul class="Disc"><li>Bilirubin</li></ul></td>
<td align="left">Normal</td>
</tr>
<tr>
<td align="left"><ul class="Disc"><li>Albumin </li></ul></td>
<td align="left">Stable and within normal limits</td>
</tr>
<tr>
<td align="left"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> Time </li></ul></td>
<td align="left">
<span class="Italics">Adults</span> less than 3 seconds prolonged<br><span class="Italics">Pediatrics</span> less than or equal to 2 seconds prolonged</td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><ul class="Disc"><li>WBC</li></ul></td>
<td align="left">Greater than or equal to 4000/mm<span class="Sup">3</span>
</td>
</tr>
<tr>
<td align="left"><ul class="Disc"><li>Platelets</li></ul></td>
<td align="left">
<span class="Italics">Adults</span> greater than or equal to 100,000/mm<span class="Sup">3</span><br><span class="Italics">Pediatrics</span> greater than or equal to 150,000/mm<span class="Sup">3</span>
</td>
</tr>
</tbody>
</table>
<p>Patients with causes of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> other than <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B or <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> should not be treated with INTRON A.  CBC and platelet counts should be evaluated prior to initiation of INTRON A therapy in order to establish baselines for monitoring potential toxicity.  These tests should be repeated at treatment Weeks 1, 2, 4, 8, 12, and 16.  Liver function tests, including serum ALT, albumin, and bilirubin, should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16.  HBeAg, HBsAg, and ALT should be evaluated at the end of therapy, as well as 3- and 6-months post-therapy, since patients may become virologic responders during the 6-month period following the end of treatment. In clinical studies in adults, 39% (15/38) of responding patients lost HBeAg 1 to 6 months following the end of INTRON A therapy.  Of responding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.</p>
<p>A transient increase in ALT greater than or equal to 2 times baseline value (flare) can occur during INTRON A therapy for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B.  In clinical trials in adults and pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy and was more frequent in responders (<span class="Italics">adults</span> 63%, 24/38; <span class="Italics">pediatrics</span> 59%, 10/17) than in nonresponders (<span class="Italics">adults</span> 27%, 13/48; <span class="Italics">pediatrics</span> 35%, 19/55).  However, in adults and pediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equal to 2 times ULN) occurred infrequently (<span class="Italics">adults</span> 2%, 2/86; <span class="Italics">pediatrics</span> 3%, 2/72) during therapy.  When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> are observed.  During ALT flare, clinical symptomatology and liver function tests including ALT, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, alkaline phosphatase, albumin, and bilirubin, should be monitored at approximately 2-week intervals (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">INTRON<span class="Sup">®</span> A is contraindicated in patients with:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to interferon alpha or any component of the product</li>
<li><span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">Autoimmune hepatitis</span></li>
<li>Decompensated liver disease</li>
</ul>
<p>INTRON A and REBETOL<span class="Sup">®</span> combination therapy is additionally contraindicated in:</p>
<ul class="Disc">
<li>Patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ribavirin or any other component of the product</li>
<li>Women who are pregnant</li>
<li>Men whose female partners are pregnant</li>
<li>Patients with hemoglobinopathies (e.g., <span class="product-label-link" type="condition" conceptid="30978" conceptname="Thalassemia">thalassemia</span> major, <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span>)</li>
<li>Patients with creatinine clearance less than 50 mL/min.</li>
</ul>
<p>See REBETOL prescribing information for additional information.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Moderate to severe adverse experiences may require modification of the patient's dosage regimen, or in some cases termination of INTRON<span class="Sup">®</span> A therapy.  Because of the <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and other "flu-like" symptoms associated with INTRON A administration, it should be used cautiously in patients with debilitating medical conditions, such as those with a history of pulmonary disease (e.g., <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>) or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus prone to <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span>.  Caution should also be observed in patients with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> (e.g., <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>) or severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></h2>
<p class="First">INTRON A therapy should be used cautiously in patients with a history of cardiovascular disease.  Those patients with a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and/or previous or current arrhythmic disorder who require INTRON A therapy should be closely monitored (see <span class="Bold"><a href="#labtest">PRECAUTIONS, Laboratory Tests</a></span>).  Cardiovascular adverse experiences, which include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, or <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> of 150 beats per minute or greater, and rarely, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been observed in some INTRON A-treated patients.  Some patients with these adverse events had no history of cardiovascular disease.  Transient <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> was reported in approximately 2% of the AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span> patients treated with INTRON A.  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may occur during INTRON A administration, or up to 2 days post-therapy, and may require supportive therapy including fluid replacement to maintain intravascular volume.</p>
<p>Supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> occurred rarely and appeared to be correlated with preexisting conditions and prior therapy with cardiotoxic agents.  These adverse experiences were controlled by modifying the dose or discontinuing treatment, but may require specific additional therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">Cerebrovascular Disorders</span></h2>
<p class="First">Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha-based therapies, including INTRON A. Events occurred in patients with few or no reported risk factors for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, including patients less than 45 years of age. Because these are spontaneous reports, estimates of frequency cannot be made and a causal relationship between interferon alpha-based therapies and these events is difficult to establish.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="neuropsychiatric"></a><a name="section-6.4"></a><p></p>
<h2>Neuropsychiatric Disorders</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">SUICIDAL BEHAVIOR</span> INCLUDING <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">SUICIDAL IDEATION</span>, SUICIDAL ATTEMPTS, AND <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">COMPLETED SUICIDES</span>, <span class="product-label-link" type="condition" conceptid="4024763" conceptname="Homicidal thoughts">HOMICIDAL IDEATION</span>, AND <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">AGGRESSIVE BEHAVIOR</span> SOMETIMES DIRECTED TOWARDS OTHERS, HAVE BEEN REPORTED IN ASSOCIATION WITH TREATMENT WITH ALPHA INTERFERONS, INCLUDING INTRON A THERAPY. If patients develop psychiatric problems, including clinical <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, it is recommended that the patients be carefully monitored during treatment and in the 6-month follow-up period.</p>
<p>INTRON A should be used with caution in patients with a history of psychiatric disorders. INTRON A therapy should be discontinued for any patient developing severe psychiatric disorder during treatment. <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Obtundation</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> have also been observed in some patients, usually elderly, treated at higher doses.  While these effects are usually rapidly reversible upon discontinuation of therapy, full resolution of symptoms has taken up to 3 weeks in a few severe episodes. If <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> persist or worsen, or suicidal or <span class="product-label-link" type="condition" conceptid="4024763" conceptname="Homicidal thoughts">homicidal ideation</span> or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> towards others is identified, discontinue treatment with INTRON A and follow the patient closely, with psychiatric intervention as appropriate. Narcotics, hypnotics, or sedatives may be used concurrently with caution and patients should be closely monitored until the adverse effects have resolved. <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal ideation</span> or attempts occurred more frequently among pediatric patients, primarily adolescents, compared to adult patients (2.4% versus 1%) during treatment and off-therapy follow-up. Cases of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> have also been observed in some patients, usually elderly, treated with higher doses of INTRON A.  </p>
<p>Treatment with interferons may be associated with exacerbated symptoms of psychiatric disorders in patients with co-occurring psychiatric and substance use disorders.  If treatment with interferons is initiated in patients with prior history or existence of psychiatric condition or with a history of substance use disorders, treatment considerations should include the need for drug screening and periodic health evaluation, including <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptom</span> monitoring.  Early intervention for re-emergence or development of neuropsychiatric symptoms and substance use is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2>Bone Marrow Toxicity</h2>
<p class="First">INTRON A therapy suppresses bone marrow function and may result in severe <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> including <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>.  It is advised that complete blood counts (CBC) be obtained pretreatment and monitored routinely during therapy (see <span class="Bold"><a href="#labtest">PRECAUTIONS, Laboratory Tests</a></span>).  INTRON A therapy should be discontinued in patients who develop severe decreases in neutrophil (less than 0.5 × 10<span class="Sup">9</span>/L) or platelet counts (less than 25 × 10<span class="Sup">9</span>/L) (see <span class="Bold"><a href="#guidelines">DOSAGE AND ADMINISTRATION, Guidelines for Dose Modification</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6"></a><p></p>
<h2>Ophthalmologic Disorders</h2>
<p class="First">Decrease or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span> including <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>, retinal artery or vein <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhages</span> and <span class="product-label-link" type="condition" conceptid="4220027" conceptname="Cotton wool spots">cotton wool spots</span>; <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, and <span class="product-label-link" type="condition" conceptid="374640" conceptname="Serous retinal detachment">serous retinal detachment</span> may be induced or aggravated by treatment with interferon alfa-2b or other alpha interferons. All patients should receive an eye examination at baseline. Patients with preexisting ophthalmologic disorders (e.g., diabetic or <span class="product-label-link" type="condition" conceptid="376965" conceptname="Hypertensive retinopathy">hypertensive retinopathy</span>) should receive periodic ophthalmologic exams during interferon alpha treatment. Any patient who develops ocular symptoms should receive a prompt and complete eye examination. Interferon alfa-2b treatment should be discontinued in patients who develop new or worsening ophthalmologic disorders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></h2>
<p class="First">Infrequently, patients receiving INTRON A therapy developed thyroid abnormalities, either hypothyroid or hyperthyroid.  The mechanism by which INTRON A may alter thyroid status is unknown.  Patients with preexisting thyroid abnormalities whose thyroid function cannot be maintained in the normal range by medication should not be treated with INTRON A.  Prior to initiation of INTRON A therapy, serum TSH should be evaluated.  Patients developing symptoms consistent with possible thyroid dysfunction during the course of INTRON A therapy should have their thyroid function evaluated and appropriate treatment instituted.  Therapy should be discontinued for patients developing thyroid abnormalities during treatment whose thyroid function cannot be normalized by medication.  Discontinuation of INTRON A therapy has not always reversed thyroid dysfunction occurring during treatment. <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus has been observed in patients treated with alpha interferons. Patients with these conditions who cannot be effectively treated by medication should not begin INTRON A therapy. Patients who develop these conditions during treatment and cannot be controlled with medication should not continue INTRON A therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></h2>
<p class="First">Hepatotoxicity, including fatality, has been observed in interferon alpha-treated patients, including those treated with INTRON A. INTRON A increases the risk of hepatic decompensation and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in patients with cirrhosis. Any patient developing liver function abnormalities during treatment should be monitored closely and if appropriate, treatment should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Pulmonary Disorders</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4222731" conceptname="Obliterative bronchiolitis">bronchiolitis obliterans</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, and <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>, some resulting in <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> and/or patient <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, may be induced or aggravated by INTRON A or other alpha interferons.  Recurrence of <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> has been observed with interferon rechallenge. The etiologic explanation for these pulmonary findings has yet to be established.  Any patient developing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, or other respiratory symptoms should have a chest X-ray taken.  If the chest X-ray shows pulmonary infiltrates or there is evidence of <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">pulmonary function impairment</span>, the patient should be closely monitored, and, if appropriate, interferon alpha treatment should be discontinued.  While this has been reported more often in patients with <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> treated with interferon alpha, it has also been reported in patients with oncologic diseases treated with interferon alpha.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune Disorders</span></h2>
<p class="First">Rare cases of autoimmune diseases including <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, Raynaud's phenomenon, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>, and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been observed in patients treated with alpha interferons, including patients treated with INTRON A.  In very rare cases the event resulted in fatality.  The mechanism by which these events developed and their relationship to interferon alpha therapy is not clear.  Any patient developing an <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorder</span> during treatment should be closely monitored and, if appropriate, treatment should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.11"></a><p></p>
<h2>Human Albumin</h2>
<p class="First">The powder formulations of this product contain albumin, a derivative of human blood.  Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.  A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote.  No cases of transmission of viral diseases or CJD have ever been identified for albumin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.12"></a><p></p>
<h2>AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span></h2>
<p class="First">INTRON A therapy should not be used for patients with rapidly progressive visceral disease (see <span class="Bold"><a href="#clinpharm">CLINICAL PHARMACOLOGY</a></span>).  Also of note, there may be synergistic adverse effects between INTRON A and zidovudine.  Patients receiving concomitant zidovudine have had a higher incidence of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> than that expected with zidovudine alone.  Careful monitoring of the WBC count is indicated in all patients who are myelosuppressed and in all patients receiving other myelosuppressive medications.  The effects of INTRON A when combined with other drugs used in the treatment of AIDS-related disease are unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.13"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span> and <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</h2>
<p class="First">Patients with decompensated liver disease, <span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span> or a history of autoimmune disease, and patients who are immunosuppressed transplant recipients should not be treated with INTRON A.  There are reports of worsening liver disease, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> following INTRON A therapy in such patients.  Therapy should be discontinued for any patient developing signs and symptoms of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic hepatitis</span> B patients with evidence of decreasing hepatic synthetic functions, such as decreasing albumin levels or prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, who nevertheless meet the entry criteria to start therapy, may be at increased risk of clinical decompensation if a flare of aminotransferases occurs during INTRON A treatment.  In such patients, if increases in ALT occur during INTRON A therapy for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, they should be followed carefully, including close monitoring of clinical symptomatology and liver function tests including ALT, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, alkaline phosphatase, albumin, and bilirubin.  In considering these patients for INTRON A therapy, the potential risks must be evaluated against the potential benefits of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.14"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> has been reported when alpha interferons were given in combination with telbivudine.  In one clinical trial, an increased risk and severity of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> was observed with the combination use of telbivudine and pegylated interferon alfa-2a as compared to telbivudine alone. The safety and efficacy of telbivudine in combination with interferons for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B has not been demonstrated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.15"></a><p></p>
<h2>Use with Ribavirin (see also REBETOL<span class="Sup">®</span> prescribing information)</h2>
<p class="First">REBETOL may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the unborn child. REBETOL therapy should not be started until a report of a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> has been obtained immediately prior to planned initiation of therapy. Patients should use at least two forms of contraception and have monthly pregnancy tests (see <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#patientinfo">PRECAUTIONS, Information for Patients</a></span>).</p>
<p>Combination treatment with INTRON A and REBETOL was associated with <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.  Hemoglobin less than 10 g/dL was observed in approximately 10% of adult and pediatric patients in clinical trials.  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> occurred within 1 to 2 weeks of initiation of ribavirin therapy. Combination treatment with INTRON A and REBETOL should <span class="Bold">not</span> be used in patients with creatinine clearance less than 50 mL/min. See REBETOL prescribing information for additional information.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Acute serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) have been observed rarely in INTRON<span class="Sup">®</span> A-treated patients; if such an acute reaction develops, the drug should be discontinued immediately and appropriate medical therapy instituted.  Transient <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> have occurred in some patients following injection, but have not necessitated treatment interruption.</p>
<p>While <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> may be related to the flu-like syndrome reported commonly in patients treated with interferon, other causes of persistent <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> should be ruled out.</p>
<p>There have been reports of interferon, including INTRON A, exacerbating preexisting <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> and <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span> as well as development of new <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>. Therefore, INTRON A therapy should be used in these patients only if the potential benefit justifies the potential risk.</p>
<p>Variations in dosage, routes of administration, and adverse reactions exist among different brands of interferon.  Therefore, do not use different brands of interferon in any single treatment regimen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Triglycerides</h2>
<p class="First">Elevated triglyceride levels have been observed in patients treated with interferons, including INTRON A therapy.  Elevated triglyceride levels should be managed as clinically appropriate.  <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> may result in <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.  Discontinuation of INTRON A therapy should be considered for patients with persistently elevated triglycerides (e.g., triglycerides greater than 1000 mg/dL) associated with symptoms of potential <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="druginteractions"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Interactions between INTRON A and other drugs have not been fully evaluated.  Caution should be exercised when administering INTRON A therapy in combination with other potentially myelosuppressive agents such as zidovudine.  Concomitant use of alpha interferon and theophylline decreases theophylline clearance, resulting in a 100% increase in serum theophylline levels.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="patientinfo"></a><a name="section-7.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients receiving INTRON A alone or in combination with REBETOL<span class="Sup">®</span> should be informed of the risks and benefits associated with treatment and should be instructed on proper use of the product.  To supplement your discussion with a patient, you may wish to provide patients with a copy of the <span class="Bold">MEDICATION GUIDE</span>.</p>
<p>Patients should be informed of, and advised to seek medical attention for, symptoms indicative of serious adverse reactions associated with this product. Such adverse reactions may include <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (<span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>), cardiovascular (<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>), ophthalmologic toxicity (decrease in/or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), and <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> (high persistent <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>).  Patients should be advised that some side effects such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and decreased concentration might interfere with the ability to perform certain tasks.  Patients who are taking INTRON A in combination with REBETOL must be thoroughly informed of the risks to a fetus.  Female patients and female partners of male patients must be told to use two forms of birth control during treatment and for six months after therapy is discontinued (see <span class="Bold"><a href="#mg">MEDICATION GUIDE</a></span>).</p>
<p>Patients should be advised to remain well hydrated during the initial stages of treatment and that use of an antipyretic may ameliorate some of the flu-like symptoms.</p>
<p>If a decision is made to allow a patient to self-administer INTRON A, they should be instructed, based on their treatment, if they should inject a dose of INTRON<span class="Sup">®</span> A subcutaneously or intramuscularly.  If it is too difficult for them to inject themselves, they should be instructed to ask someone who has been trained to give the injection to them.  Patients should be instructed on the importance of site selection for self-administering the injection, as well as the importance on rotating the injection sites.  A puncture resistant container for the disposal of needles and syringes should be supplied.  Patients self-administering INTRON A should be instructed on the proper disposal of needles and syringes and cautioned against reuse.</p>
<p>Patients should be instructed that the Sterile Water for Injection vial supplied with Intron A Powder for Injection contains an excess amount of diluent (5 mL) and only 1 mL should be withdrawn to reconstitute Intron A Powder for Injection. The vial of Sterile Water for Injection is intended for single use only. Discard the unused portion of sterile water. Do not save or reuse.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Dental and Periodontal Disorders</h2>
<p class="First">Dental and periodontal disorders have been reported in patients receiving ribavirin and interferon combination therapy. In addition, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> could have a damaging effect on teeth and mucous membranes of the mouth during long-term treatment with the combination of REBETOL and interferon alfa-2b. Patients should brush their teeth thoroughly twice daily and have regular dental examinations. In addition, some patients may experience <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. If this reaction occurs, they should be advised to rinse out their mouth thoroughly afterwards.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="labtest"></a><a name="section-7.6"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In addition to those tests normally required for monitoring patients, the following laboratory tests are recommended for all patients on INTRON A therapy, prior to beginning treatment and then periodically thereafter.</p>
<ul class="Disc">
<li>Standard hematologic tests — including hemoglobin, complete and differential white blood cell counts, and platelet count.</li>
<li>Blood chemistries — electrolytes, liver function tests, and TSH.</li>
<li>Monitor hepatic function with serum bilirubin, ALT (alanine transaminase), AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>), alkaline phosphatase, and LDH (lactate dehydrogenase) at 2, 8 and 12 weeks following initiation of INTRON A, then every 6 months while receiving INTRON A. Permanently discontinue INTRON A for evidence of severe (Grade 3) hepatic injury or hepatic decompensation (Child-Pugh score &gt;6 [class B and C]).</li>
</ul>
<p>Those patients who have preexisting cardiac abnormalities and/or are in advanced stages of cancer should have electrocardiograms taken prior to and during the course of treatment.</p>
<p>Mild-to-moderate <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and elevated serum liver enzyme (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) levels have been reported with intralesional administration of INTRON A (see <span class="Bold"><a href="#adverse">ADVERSE REACTIONS</a></span>); therefore, the monitoring of these laboratory parameters should be considered.</p>
<p>Baseline chest X-rays are suggested and should be repeated if clinically indicated.</p>
<p>For malignant melanoma patients, differential WBC count and liver function tests should be monitored weekly during the induction phase of therapy and monthly during the maintenance phase of therapy.</p>
<p>For specific recommendations in <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> and <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, see <span class="Bold"><a href="#indications">INDICATIONS AND USAGE</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies with INTRON A have not been performed to determine carcinogenicity.</p>
<p>Interferon may impair fertility.  In studies of interferon administration in nonhuman primates, menstrual cycle abnormalities have been observed.  Decreases in serum estradiol and progesterone concentrations have been reported in women treated with human leukocyte interferon.<span class="Sup">12</span> Therefore, fertile women should not receive INTRON A therapy unless they are using effective contraception during the therapy period. INTRON A therapy should be used with caution in fertile men.</p>
<p>Mutagenicity studies have demonstrated that INTRON A is not mutagenic.</p>
<p>Studies in mice (0.1, 1.0 million IU/day), rats (4, 20, 100 million IU/kg/day), and cynomolgus monkeys (1.1 million IU/kg/day; 0.25, 0.75, 2.5 million IU/kg/day) injected with INTRON A for up to 9 days, 3 months, and 1 month, respectively, have revealed no evidence of toxicity.  However, in cynomolgus monkeys (4, 20, 100 million IU/kg/day) injected daily for 3 months with INTRON A, toxicity was observed at the mid and high doses and mortality was observed at the high dose.</p>
<p>However, due to the known species-specificity of interferon, the effects in animals are unlikely to be predictive of those in man.</p>
<p>INTRON A in combination with REBETOL should be used with caution in fertile men.  See the REBETOL prescribing information for additional information.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.8"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">INTRON A has been shown to have abortifacient effects in <span class="Italics">Macaca mulatta</span> (rhesus monkeys) at 15 and 30 million IU/kg (estimated human equivalent of 5 and 10 million IU/kg, based on body surface area adjustment for a 60-kg adult).  There are no adequate and well-controlled studies in pregnant women.  INTRON A therapy should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.9"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category X</span> applies to combination treatment with INTRON A and REBETOL (see <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>). See REBETOL prescribing information for additional information. Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. REBETOL therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant. See <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span> and the REBETOL prescribing information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10"></a><p></p>
<h2>Ribavirin Pregnancy Registry</h2>
<p class="First"><span class="Bold">A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.11"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk.  However, studies in mice have shown that mouse interferons are excreted into the milk.  Because of the potential for serious adverse reactions from the drug in nursing infants, a decision should be made whether to discontinue nursing or to discontinue INTRON A therapy, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-7.12"></a><p></p>
<h2>Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.12.1"></a><p></p>
<h3>General</h3>
<p class="First">Safety and effectiveness in pediatric patients have not been established for indications other than <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B and <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.12.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</h3>
<p class="First">Safety and effectiveness in pediatric patients ranging in age from 1 to 17 years have been established based upon one controlled clinical trial (see <span class="Bold"><a href="#clinpharm">CLINICAL PHARMACOLOGY</a>, <a href="#indications">INDICATIONS AND USAGE</a>,</span> and <span class="Bold"><a href="#chbp">DOSAGE AND ADMINISTRATION, <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B Pediatrics</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.12.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span></h3>
<p class="First">Safety and effectiveness in pediatric patients ranging in age from 3 to 16 years have been established based upon clinical studies in 118 patients. See REBETOL prescribing information for additional information. <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal ideation</span> or attempts occurred more frequently among pediatric patients compared to adult patients (2.4% versus 1%) during treatment and off-therapy follow-up (see <span class="Bold"><a href="#neuropsychiatric">WARNINGS, Neuropsychiatric Disorders</a></span>). During a 48-week course of therapy there was a decrease in the rate of linear growth (mean percentile assignment decrease of 7%) and a decrease in the rate of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (mean percentile assignment decrease of 9%). A general reversal of these trends was noted during the 24-week post-treatment period.</p>
<p>Long-term data in a limited number of patients suggests that combination therapy may induce a growth inhibition that results in reduced final adult height in some patients (see <span class="Bold"><a href="#chcp">ADVERSE REACTIONS, <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span> Pediatrics</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.13"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In all clinical studies of INTRON A, including studies as monotherapy and in combination with REBETOL (ribavirin USP) Capsules, only a small percentage of the subjects were aged 65 and over.  These numbers were too few to determine if they respond differently from younger subjects except for the clinical trials of INTRON A in combination with REBETOL, where elderly subjects had a higher frequency of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (67%) than did younger patients (28%).</p>
<p>In a database consisting of clinical study and postmarketing reports for various indications, cardiovascular adverse events and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> were reported more frequently in elderly patients receiving INTRON A therapy compared to younger patients.</p>
<p>In general, INTRON A therapy should be administered to elderly patients cautiously, reflecting the greater frequency of decreased hepatic, renal, bone marrow, and/or cardiac function and concomitant disease or other drug therapy.  INTRON A is known to be substantially excreted by the kidney, and the risk of adverse reactions to INTRON A may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients often have decreased renal function, patients should be carefully monitored during treatment, and dose adjustments made based on symptoms and/or laboratory abnormalities (see <span class="Bold"><a href="#clinpharm">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">The adverse experiences listed below were reported to be possibly or probably related to INTRON<span class="Sup">®</span> A therapy during clinical trials.  Most of these adverse reactions were mild to moderate in severity and were manageable.  Some were transient and most diminished with continued therapy.</p>
<p>The most frequently reported adverse reactions were "flu-like" symptoms, particularly <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.  More severe toxicities are observed generally at higher doses and may be difficult for patients to tolerate.</p>
<table width="100%">
<caption><span>TREATMENT-RELATED ADVERSE EXPERIENCES BY INDICATION</span></caption>
<col align="left" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<col align="center" valign="top" width="6%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="10"><span class="Underline">Dosing Regimens<br> Percentage (%) of Patients<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a></span></th>
</tr>
<tr>
<th align="left"></th>
<th align="center">MALIGNANT MELANOMA</th>
<th align="center">FOLLICULAR <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">LYMPHOMA</span></th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">HAIRY CELL LEUKEMIA</span></th>
<th align="center">CONDYLOMATA ACUMINATA</th>
<th align="center" colspan="2">AIDS-RELATED KAPOSI'S <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">SARCOMA</span></th>
<th align="center"><span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">CHRONIC HEPATITIS C</span><a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a>
</th>
<th align="center" colspan="3"><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">CHRONIC HEPATITIS</span> B</th>
</tr>
<tr>
<th align="left"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center" colspan="2">Adults</th>
<th align="center">Pediatrics</th>
</tr>
<tr>
<th class="Botrule" align="left"></th>
<th class="Botrule" align="center"><span class="Italics">20 MIU/m<span class="Sup">2</span><br> Induction (IV)<br> 10 MIU/m<span class="Sup">2</span><br> Maintenance<br> (SC)</span></th>
<th class="Botrule" align="center"><span class="Italics">5 MIU 												<br>TIW/SC<br></span></th>
<th class="Botrule" align="center"><span class="Italics">2 MIU/m<span class="Sup">2</span><br>TIW/SC<br></span></th>
<th class="Botrule" align="center"><span class="Italics">1 MIU/lesion</span></th>
<th class="Botrule" align="center"><span class="Italics">30 MIU/m<span class="Sup">2</span><br>TIW/SC<br></span></th>
<th class="Botrule" align="center"><span class="Italics">35 MIU 												<br>QD/SC<br></span></th>
<th class="Botrule" align="center"><span class="Italics">3 MIU 												<br>TIW<br></span></th>
<th class="Botrule" align="center"><span class="Italics">5 MIU 												<br>QD<br></span></th>
<th class="Botrule" align="center"><span class="Italics">10 MIU 												<br>TIW<br></span></th>
<th class="Botrule" align="center"><span class="Italics">6 MIU/m<span class="Sup">2</span><br>TIW<br></span></th>
</tr>
<tr class="Botrule Last">
<th align="left"><span class="Italics">ADVERSE EXPERIENCE</span></th>
<th align="center">N=143</th>
<th align="center">N=135</th>
<th align="center">N=145</th>
<th align="center">N=352</th>
<th align="center">N=74</th>
<th align="center">N=29</th>
<th align="center">N=183</th>
<th align="center">N=101</th>
<th align="center">N=78</th>
<th align="center">N=116</th>
</tr>
</thead>
<tfoot><tr><td colspan="11" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Dash (--) indicates not reported</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>Percentages based upon a summary of all adverse events during 18 to 24 months of treatment</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> was reported with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> as a single term</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">§</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>/<span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span></dd>
<dt><a name="footnote-22" href="#footnote-reference-22">¶</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span> was reported with <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> as a single term</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">#</a></dt>
<dd>Predominantly <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="Italics Underline">Application-Site Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">20</td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  injection site<br>  <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span></td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">5</td>
<td align="center">3</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr class="Botrule">
<td align="left">  other (≤5%)</td>
<td align="left" colspan="10">burning, <span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">injection site bleeding</span>, <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span> (5% in <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B pediatrics), <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood Disorders</span> (&lt;5%)</span></td>
<td align="left" colspan="10"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">anemia hypochromic</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (9% in <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>, 14% in <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B pediatrics), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (10% in <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>) (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> 8% in malignant melanoma), <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenia purpura</span></td>
</tr>
<tr>
<td align="left"><span class="Italics Underline">Body as a Whole</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">&lt;1</td>
<td align="center">--</td>
<td align="center">10</td>
<td align="center">&lt;1</td>
<td align="center">3</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span></td>
<td align="center">3</td>
<td align="center">13</td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
<td align="center">5</td>
<td align="center">3</td>
<td align="center">10</td>
<td align="center">2</td>
<td align="center">5</td>
<td align="center">3</td>
</tr>
<tr class="Botrule">
<td align="left" valign="top">  other (≤5%)</td>
<td align="left" colspan="10"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> nonspecific, <span class="product-label-link" type="condition" conceptid="316084" conceptname="Lymphadenitis">lymphadenitis</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4163232" conceptname="Mastitis">mastitis</span>, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>, <span class="product-label-link" type="condition" conceptid="4173307" conceptname="Poor peripheral circulation">poor peripheral circulation</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (6% in follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), <span class="product-label-link" type="condition" conceptid="4289731" conceptname="Thrombophlebitis of breast">phlebitis superficial</span>, scrotal/<span class="product-label-link" type="condition" conceptid="201346" conceptname="Edema of penis">penile edema</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span></td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Cardiovascular System Disorders (&lt;5%)</span></td>
<td align="left" colspan="10">angina, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disorder</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, heart valve disorder, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (9% in <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, Raynaud's disease, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="441644" conceptname="Varicose veins of legs in pregnancy and the puerperium">varicose vein</span></td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Endocrine System Disorders (&lt;5%)</span></td>
<td align="left" colspan="10">aggravation of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilism</span></td>
</tr>
<tr>
<td align="left"><span class="Italics Underline">Flu-like Symptoms</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></td>
<td align="center">81</td>
<td align="center">56</td>
<td align="center">68</td>
<td align="center">56</td>
<td align="center">47</td>
<td align="center">55</td>
<td align="center">34</td>
<td align="center">66</td>
<td align="center">86</td>
<td align="center">94</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></td>
<td align="center">62</td>
<td align="center">21</td>
<td align="center">39</td>
<td align="center">47</td>
<td align="center">36</td>
<td align="center">21</td>
<td align="center">43</td>
<td align="center">61</td>
<td align="center">44</td>
<td align="center">57</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></td>
<td align="center">54</td>
<td align="center">--</td>
<td align="center">46</td>
<td align="center">45</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></td>
<td align="center">75</td>
<td align="center">16</td>
<td align="center">39</td>
<td align="center">44</td>
<td align="center">34</td>
<td align="center">28</td>
<td align="center">43</td>
<td align="center">59</td>
<td align="center">40</td>
<td align="center">27</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></td>
<td align="center">96</td>
<td align="center">8</td>
<td align="center">61</td>
<td align="center">18</td>
<td align="center">84</td>
<td align="center">48</td>
<td align="center">23</td>
<td align="center">75</td>
<td align="center">69</td>
<td align="center">71</td>
</tr>
<tr>
<td align="left">  increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></td>
<td align="center">6</td>
<td align="center">13</td>
<td align="center">8</td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">21</td>
<td align="center">4</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></td>
<td align="center">--</td>
<td align="center">63</td>
<td align="center">7</td>
<td align="center">--</td>
<td align="center">11</td>
<td align="center">--</td>
<td align="center">40</td>
<td align="center">5</td>
<td align="center">15</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span></td>
<td align="center">2</td>
<td align="center">7</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">30</td>
<td align="center">14</td>
<td align="center">16</td>
<td align="center">38</td>
<td align="center">42</td>
<td align="center">30</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></td>
<td align="center">6</td>
<td align="center">8</td>
<td align="center">8</td>
<td align="center">9</td>
<td align="center">--</td>
<td align="center">3</td>
<td align="center">16</td>
<td align="center">19</td>
<td align="center">8</td>
<td align="center">15</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></td>
<td align="center">23</td>
<td align="center">--</td>
<td align="center">12</td>
<td align="center">9</td>
<td align="center">7</td>
<td align="center">24</td>
<td align="center">9</td>
<td align="center">13</td>
<td align="center">10</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms</td>
<td align="center">10</td>
<td align="center">18</td>
<td align="center">37</td>
<td align="center">--</td>
<td align="center">45</td>
<td align="center">79</td>
<td align="center">26</td>
<td align="center">5</td>
<td align="center">--</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></td>
<td align="center">--</td>
<td align="center">15</td>
<td align="center">19</td>
<td align="center">6</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">19</td>
<td align="center">--</td>
<td align="center">22</td>
<td align="center">28</td>
<td align="center">5</td>
<td align="center">6</td>
<td align="center">5</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></td>
<td align="center">2</td>
<td align="center">8</td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">28</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></td>
<td align="center">6</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">14</td>
<td align="center">5</td>
<td align="center">--</td>
<td align="center">13</td>
<td align="center">9</td>
<td align="center">6</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (unspecified)</td>
<td align="center">15</td>
<td align="center">9</td>
<td align="center">18</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr class="Botrule">
<td align="left">  other (&lt;5%)</td>
<td align="left" colspan="10"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain substernal</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span></td>
</tr>
<tr>
<td align="left"><span class="Italics Underline">Gastrointestinal System Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></td>
<td align="center">35</td>
<td align="center">19</td>
<td align="center">18</td>
<td align="center">2</td>
<td align="center">18</td>
<td align="center">45</td>
<td align="center">13</td>
<td align="center">19</td>
<td align="center">8</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span></td>
<td align="center">69</td>
<td align="center">21</td>
<td align="center">19</td>
<td align="center">1</td>
<td align="center">38</td>
<td align="center">41</td>
<td align="center">14</td>
<td align="center">43</td>
<td align="center">53</td>
<td align="center">43</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td align="center">66</td>
<td align="center">24</td>
<td align="center">21</td>
<td align="center">17</td>
<td align="center">28</td>
<td align="center">21</td>
<td align="center">19</td>
<td align="center">50</td>
<td align="center">33</td>
<td align="center">18</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span></td>
<td align="center">24</td>
<td align="center">2</td>
<td align="center">13</td>
<td align="center">&lt;1</td>
<td align="center">5</td>
<td align="center">7</td>
<td align="center">2</td>
<td align="center">10</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></td>
<td align="center">2</td>
<td align="center">20</td>
<td align="center">&lt;5</td>
<td align="center">1</td>
<td align="center">5</td>
<td align="center">21</td>
<td align="center">16</td>
<td align="center">5</td>
<td align="center">4</td>
<td align="center">23</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span></td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">&lt;1</td>
<td align="center">--</td>
<td align="center">10</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">--</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td align="center"><a name="footnote-reference-20" href="#footnote-20" class="Sup">‡</a></td>
<td align="center">32</td>
<td align="center">6</td>
<td align="center">2</td>
<td align="center">11</td>
<td align="center">14</td>
<td align="center">8</td>
<td align="center">7</td>
<td align="center">10</td>
<td align="center">27</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></td>
<td align="center">1</td>
<td align="center">14</td>
<td align="center">&lt;1</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">10</td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">--</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span></td>
<td align="center">2<a name="footnote-reference-21" href="#footnote-21" class="Sup">§</a>
</td>
<td align="center">7<a href="#footnote-21" class="Sup">§</a>
</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">14</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span></td>
<td align="center">--</td>
<td align="center">2</td>
<td align="center">--</td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">--</td>
<td align="center">7</td>
<td align="center">3</td>
<td align="center">8</td>
<td align="center">3</td>
</tr>
<tr class="Botrule">
<td align="left">  other (&lt;5%)</td>
<td align="left" colspan="10">abdominal <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span> (7% in follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, gastrointestinal <span class="product-label-link" type="condition" conceptid="44791183" conceptname="Pale mucous membrane">mucosal discoloration</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gingival bleeding</span>, gum <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">halitosis</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, increased saliva, intestinal disorder, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="4330466" conceptname="Bleeding from mouth">oral hemorrhage</span>, oral <span class="product-label-link" type="condition" conceptid="4167091" conceptname="Leukoplakia">leukoplakia</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> after stool, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4260546" conceptname="Ulcerative stomatitis">stomatitis ulcerative</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">tongue disorder</span>, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span></td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Liver and Biliary System Disorders (&lt;5%)</span></td>
<td align="left" colspan="10">abnormal hepatic function tests, <span class="product-label-link" type="condition" conceptid="4291807" conceptname="Biliary colic">biliary pain</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, increased lactate dehydrogenase, increased transaminases (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/SGPT) (elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> 63% in malignant melanoma and 24% in follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">right upper quadrant pain</span> (15% in <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>), and very rarely, <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></td>
</tr>
<tr>
<td align="left"><span class="Italics Underline">Musculoskeletal System Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span></td>
<td align="center">--</td>
<td align="center">18</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">21</td>
<td align="center">9</td>
<td align="center">1</td>
<td align="center">10</td>
</tr>
<tr class="Botrule">
<td align="left">  other (&lt;5%)</td>
<td align="left" colspan="10"><span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis aggravated</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">bone disorder</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>, <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle atrophy</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="320749" conceptname="Polyarteritis nodosa">polyarteritis nodosa</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="4223530" conceptname="Spondylitis">spondylitis</span></td>
</tr>
<tr>
<td align="left"><span class="Italics Underline">Nervous System and Psychiatric Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></td>
<td align="center">40</td>
<td align="center">9</td>
<td align="center">6</td>
<td align="center">3</td>
<td align="center">9</td>
<td align="center">28</td>
<td align="center">19</td>
<td align="center">17</td>
<td align="center">6</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></td>
<td align="center">13</td>
<td align="center">13</td>
<td align="center">6</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">21</td>
<td align="center">5</td>
<td align="center">6</td>
<td align="center">3</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  impaired concentration</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">&lt;1</td>
<td align="center">3</td>
<td align="center">14</td>
<td align="center">3</td>
<td align="center">8</td>
<td align="center">5</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span></td>
<td align="center"><a name="footnote-reference-22" href="#footnote-22" class="Sup">¶</a></td>
<td align="center">1</td>
<td align="center">&lt;5</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">14</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></td>
<td align="center">8</td>
<td align="center">2</td>
<td align="center">&lt;5</td>
<td align="center">4</td>
<td align="center">12</td>
<td align="center">10</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span></td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">&lt;5</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">10</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">13</td>
<td align="center">16</td>
<td align="center">12</td>
<td align="center">22</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">&lt;5</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">--</td>
<td align="center">33<a name="footnote-reference-23" href="#footnote-23" class="Sup">#</a>
</td>
<td align="center">14</td>
<td align="center">9</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></td>
<td align="center">1</td>
<td align="center">9</td>
<td align="center">5</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">5</td>
<td align="center">2</td>
<td align="center">--</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></td>
<td align="center">5</td>
<td align="center">4</td>
<td align="center">--</td>
<td align="center">&lt;1</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">12</td>
<td align="center">11</td>
<td align="center">6</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">3</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">--</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  decreased libido</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">&lt;5</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">5</td>
<td align="center">1</td>
<td align="center">--</td>
</tr>
<tr class="Botrule">
<td align="left">  other (&lt;5%)</td>
<td align="left" colspan="10">abnormal coordination, abnormal dreaming, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, aggravated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> (7% in <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B pediatrics), <span class="product-label-link" type="condition" conceptid="4010023" conceptname="Alcohol intolerance">alcohol intolerance</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, Bell's <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">palsy</span>, CNS dysfunction, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, feeling of ebriety, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, hearing disorder, hearing impairment, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, impaired consciousness, <span class="product-label-link" type="condition" conceptid="78771" conceptname="Labyrinthine dysfunction">labyrinthine disorder</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">manic depression</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">paroniria</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">polyneuropathy</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, speech disorder, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (8% in follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>)</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Reproduction System Disorders (&lt;5%)</span></td>
<td align="left" colspan="10"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> (12% in follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">menstrual irregularity</span>, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, <span class="product-label-link" type="condition" conceptid="196158" conceptname="Disorder of penis">penis disorder</span>, <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>, <span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">vaginal dryness</span></td>
</tr>
<tr>
<td align="left"><span class="Italics Underline">Resistance Mechanism Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span></td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">&lt;1</td>
<td align="center">--</td>
<td align="center">17</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  herpes simplex</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">3</td>
<td align="center">1</td>
<td align="center">5</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr class="Botrule">
<td align="left">  other (&lt;5%)</td>
<td align="left" colspan="10"><span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, hemophilus, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">infection bacterial</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> nonspecific (7% in follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infection parasitic</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="380403" conceptname="External hordeolum">stye</span>, trichomonas, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> (7% in <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>)</td>
</tr>
<tr>
<td align="left"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></td>
<td align="center">15</td>
<td align="center">14</td>
<td align="center">&lt;1</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">34</td>
<td align="center">3</td>
<td align="center">5</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span></td>
<td align="center">6</td>
<td align="center">13</td>
<td align="center">&lt;1</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">31</td>
<td align="center">1</td>
<td align="center">4</td>
<td align="center">--</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></td>
<td align="center">2</td>
<td align="center">8</td>
<td align="center">&lt;5</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">31</td>
<td align="center">3</td>
<td align="center">7</td>
<td align="center">1</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span></td>
<td align="center">1	</td>
<td align="center">4</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">21</td>
<td align="center">2</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>	</td>
<td align="center">2</td>
<td align="center">7</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">14</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span></td>
<td align="center">1</td>
<td align="center">7</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">10</td>
<td align="center">&lt;1</td>
<td align="center">4</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr class="Botrule">
<td align="left">  other (≤5%)</td>
<td align="left" colspan="10"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> (10% in follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> (7% in <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B pediatrics), <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">lung fibrosis</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="315361" conceptname="Orthopnea">orthopnea</span>, <span class="product-label-link" type="condition" conceptid="4330445" conceptname="Pleuritic pain">pleural pain</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>, <span class="product-label-link" type="condition" conceptid="4270490" conceptname="Tracheitis">tracheitis</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span></td>
</tr>
<tr>
<td align="left"><span class="Italics Underline">Skin and Appendages Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span></td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">8</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">--	</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span></td>
<td align="center">29</td>
<td align="center">23</td>
<td align="center">8</td>
<td align="center">--</td>
<td align="center">12</td>
<td align="center">31</td>
<td align="center">28</td>
<td align="center">26</td>
<td align="center">38</td>
<td align="center">17</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td align="center">--</td>
<td align="center">10</td>
<td align="center">11</td>
<td align="center">1</td>
<td align="center">7</td>
<td align="center">--</td>
<td align="center">9</td>
<td align="center">6</td>
<td align="center">4</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></td>
<td align="center">19</td>
<td align="center">13</td>
<td align="center">25</td>
<td align="center">--</td>
<td align="center">9</td>
<td align="center">10</td>
<td align="center">5</td>
<td align="center">8</td>
<td align="center">1</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">9</td>
<td align="center">--</td>
<td align="center">9</td>
<td align="center">10</td>
<td align="center">4</td>
<td align="center">3</td>
<td align="center">--</td>
<td align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td align="left">  other (&lt;5%)</td>
<td align="left" colspan="10">abnormal hair texture, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> of the hand, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="4028560" conceptname="Lichenoid dermatitis">dermatitis lichenoides</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4142366" conceptname="Ten">epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, increased hair growth, <span class="product-label-link" type="condition" conceptid="379814" conceptname="Dislocation of lacrimal gland">lacrimal gland disorder</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipoma</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4166542" conceptname="Melanosis">melanosis</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorders</span>, nonherpetic <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">cold sores</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">pruritus genital</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis aggravated</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> (5% in <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="137351" conceptname="Epidermoid cyst of skin">sebaceous cyst</span>, <span class="product-label-link" type="condition" conceptid="4048466" conceptname="Achromia of skin">skin depigmentation</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="4042856" conceptname="Fibrous nodule">skin nodule</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="138502" conceptname="Vitiligo">vitiligo</span></td>
</tr>
<tr class="Botrule">
<td align="left"><span class="Italics">Urinary System Disorders (&lt;5%)</span></td>
<td align="left" colspan="10">albumin/protein in urine, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, increased BUN, micturition disorder, micturition frequency, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> (10% in follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> (5% in <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span>)</td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">Vision Disorders (&lt;5%)</span></td>
<td align="left" colspan="10"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">Hairy Cell Leukemia</span></h2>
<p class="First">The adverse reactions most frequently reported during clinical trials in 145 patients with <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> were the "flu-like" symptoms of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (68%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (61%), and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (46%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Malignant Melanoma</h2>
<p class="First">The INTRON A dose was modified because of adverse events in 65% (n=93) of the patients.  INTRON A therapy was discontinued because of adverse events in 8% of the patients during induction and 18% of the patients during maintenance.  The most frequently reported adverse reaction was <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, which was observed in 96% of patients.  Other adverse reactions that were recorded in greater than 20% of INTRON A-treated patients included <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (92%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (81%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (75%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (69%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>/<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (66%), increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (63%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (62%), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (54%), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (40%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (35%), <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> (29%), altered taste sensation (24%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (23%), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (22%).</p>
<p>Adverse reactions classified as severe or life threatening (ECOG Toxicity Criteria grade 3 or 4) were recorded in 66% and 14% of INTRON A-treated patients, respectively.  Severe adverse reactions recorded in greater than 10% of INTRON A-treated patients included <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>/<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (26%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (23%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (18%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (17%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (17%), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> (16%), and increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (14%).  Grade 4 <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> was recorded in 4% and grade 4 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> was recorded in 2% of INTRON A-treated patients.  No other grade 4 AE was reported in more than 2 INTRON A-treated patients.  Lethal hepatotoxicity occurred in 2 INTRON A-treated patients early in the clinical trial.  No subsequent lethal hepatotoxicities were observed with adequate monitoring of liver function tests (see <span class="Bold"><a href="#labtest">PRECAUTIONS, Laboratory Tests</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">Ninety-six percent of patients treated with CHVP plus INTRON A therapy and 91% of patients treated with CHVP alone reported an adverse event of any severity.  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, increased hepatic enzymes, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, "flu-like" symptoms, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> occurred more frequently in the CHVP plus INTRON A-treated patients than in patients treated with CHVP alone.  Adverse reactions classified as severe or life threatening (World Health Organization grade 3 or 4) recorded in greater than 5% of CHVP plus INTRON A-treated patients included <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (34%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (10%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (10%).  The incidence of neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was 6% in CHVP plus INTRON A versus 2% in CHVP alone.  One patient in each treatment group required hospitalization.</p>
<p>Twenty-eight percent of CHVP plus INTRON A-treated patients had a temporary modification/interruption of their INTRON A therapy, but only 13 patients (10%) permanently stopped INTRON A therapy because of toxicity.  There were four <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> on study; two patients committed <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> in the CHVP plus INTRON A arm and two patients in the CHVP arm had unwitnessed <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>.  Three patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B (one of whom also had <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span>) developed hepatotoxicity leading to discontinuation of INTRON A. Other reasons for discontinuation included intolerable <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (5/135), severe <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu symptoms</span> (2/135), and one patient each with exacerbation of <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, and decreased <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>Condylomata Acuminata</h2>
<p class="First">Eighty-eight percent (311/352) of patients treated with INTRON A for condylomata acuminata who were evaluable for safety reported an adverse reaction during treatment.  The incidence of the adverse reactions reported increased when the number of treated lesions increased from one to five.  All 40 patients who had five <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span> treated reported some type of adverse reaction during treatment.</p>
<p>Adverse reactions and abnormal laboratory test values reported by patients who were re-treated were qualitatively and quantitatively similar to those reported during the initial INTRON A treatment period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span></h2>
<p class="First">In patients with AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span>, some type of adverse reaction occurred in 100% of the 74 patients treated with 30 million IU/m<span class="Sup">2</span> three times a week and in 97% of the 29 patients treated with 35 million IU per day.</p>
<p>Of these adverse reactions, those classified as severe (World Health Organization grade 3 or 4) were reported in 27% to 55% of patients.  Severe adverse reactions in the 30 million IU/m<span class="Sup">2</span> TIW study included: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (20%), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms (15%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (12%), <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (4%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (4%), <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (3%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (3%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (3%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1% each).  Severe adverse reactions for patients who received the 35 million IU QD included:  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (24%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (17%), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms (14%), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (14%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (10%), <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (7%), and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI hemorrhage</span>, abnormal hepatic function, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> (1 patient each).  Overall, the incidence of severe toxicity was higher among patients who received the 35 million IU per day dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7.1"></a><p></p>
<h3>Adults</h3>
<p class="First">Two studies of extended treatment (18-24 months) with INTRON A show that approximately 95% of all patients treated experience some type of adverse event and that patients treated for extended duration continue to experience adverse events throughout treatment.  Most adverse events reported are mild to moderate in severity.  However, 29/152 (19%) of patients treated for 18 to 24 months experienced a serious adverse event compared to 11/163 (7%) of those treated for 6 months.  Adverse events which occur or persist during extended treatment are similar in type and severity to those occurring during short-course therapy.</p>
<p>Of the patients achieving a complete response after 6 months of therapy, 12/79 (15%) subsequently discontinued INTRON A treatment during extended therapy because of adverse events, and 23/79 (29%) experienced severe adverse events (WHO grade 3 or 4) during extended therapy.</p>
<p>In patients using combination treatment with INTRON A and REBETOL, the primary toxicity observed was <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.  Reductions in hemoglobin levels occurred within the first 1 to 2 weeks of therapy.  Cardiac and pulmonary events associated with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> occurred in approximately 10% of patients treated with INTRON A/REBETOL therapy.  See REBETOL prescribing information for additional information.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="chcp"></a><a name="section-8.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.8.1"></a><p></p>
<h3>Pediatrics</h3>
<p class="First">In pediatric patients with <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> treated with INTRON A 3 MIU/m<span class="Sup">2</span> three times weekly and REBETOL 15 mg/kg per day, all subjects (n=118) had at least one adverse event during 24-48 weeks of treatment, of which 80% were considered to be mild or moderate in severity. Six percent discontinued therapy due to adverse reactions and dose modifications were required in 30% of subjects, most commonly for <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Adverse events occurring in more than 50% of subjects included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. Adverse events occurring in 20-50% of subjects included <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. The most common laboratory test abnormalities were <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (34%) and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (27%). <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> was reported in 13% (n=15) of children. Three of these subjects had <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, and one <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span>. <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span> and slowed growth are common in pediatric patients during combination therapy with INTRON A and REBETOL. Following treatment, rebound growth and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in most subjects. Long-term follow-up data in pediatric subjects, however, indicates that INTRON A in combination with REBETOL may induce a growth inhibition that results in reduced adult height in some patients (see <span class="Bold"><a href="#pediatric">PRECAUTIONS, Pediatric Use</a>)</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.1"></a><p></p>
<h3>Adults</h3>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, some type of adverse reaction occurred in 98% of the 101 patients treated at 5 million IU QD and 90% of the 78 patients treated at 10 million IU TIW.  Most of these adverse reactions were mild to moderate in severity, were manageable, and were reversible following the end of therapy.</p>
<p>Adverse reactions classified as severe (causing a significant interference with normal daily activities or clinical state) were reported in 21% to 44% of patients.  The severe adverse reactions reported most frequently were the "flu-like" symptoms of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (28%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (15%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (4%), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span> (4%), and other severe "flu-like" symptoms, which occurred in 1% to 3% of patients.  Other severe adverse reactions occurring in more than one patient were <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> (8%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (6%), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (3%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2%).</p>
<p>To manage side effects, the dose was reduced, or INTRON A therapy was interrupted in 25% to 38% of patients.  Five percent of patients discontinued treatment due to adverse experiences.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.10.1"></a><p></p>
<h3>Pediatrics</h3>
<p class="First">In pediatric patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B (n=72) during 16-24 weeks of treatment, the most frequently reported adverse events were those commonly associated with interferon treatment: flu-like symptoms (100%), gastrointestinal system disorders (46%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (40%).  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (13%) and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (3%) were also reported.  None of the adverse events was life threatening and most were moderate to severe and resolved upon dose reduction or drug discontinuation.</p>
<table width="100%">
<caption><span>ABNORMAL LABORATORY TEST VALUES BY INDICATION</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="10"><span class="Underline">Dosing Regimens<br> Percentage (%) of Patients</span></th>
</tr>
<tr>
<th align="left"></th>
<th align="center">MALIGNANT MELANOMA</th>
<th align="center">FOLLICULAR <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">LYMPHOMA</span></th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">HAIRY CELL LEUKEMIA</span></th>
<th align="center">CONDYLOMATA ACUMINATA</th>
<th align="center" colspan="2">AIDS-RELATED KAPOSI'S <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">SARCOMA</span></th>
<th align="center"><span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">CHRONIC HEPATITIS C</span></th>
<th align="center" colspan="3"><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">CHRONIC HEPATITIS</span> B</th>
</tr>
<tr>
<th align="left"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center"></th>
<th align="center" colspan="2">Adults</th>
<th align="center">Pediatrics</th>
</tr>
<tr>
<th class="Botrule" align="left"></th>
<th class="Botrule" align="center"><span class="Italics">20 MIU/m<span class="Sup">2</span><br> Induction (IV)<br> 10 MIU/m<span class="Sup">2</span><br> Maintenance<br> (SC)</span></th>
<th class="Botrule" align="center"><span class="Italics">5 MIU 														<br>TIW/SC<br></span></th>
<th class="Botrule" align="center"><span class="Italics">2 MIU/m<span class="Sup">2</span><br>TIW/SC<br></span></th>
<th class="Botrule" align="center"><span class="Italics">1 MIU/lesion</span></th>
<th class="Botrule" align="center"><span class="Italics">30 MIU/m<span class="Sup">2</span><br>TIW/SC<br></span></th>
<th class="Botrule" align="center"><span class="Italics">35 MIU 														<br>QD/SC<br></span></th>
<th class="Botrule" align="center"><span class="Italics">3 MIU 														<br>TIW<br></span></th>
<th class="Botrule" align="center"><span class="Italics">5 MIU 														<br>QD<br></span></th>
<th class="Botrule" align="center"><span class="Italics">10 MIU 														<br>TIW<br></span></th>
<th class="Botrule" align="center"><span class="Italics">6 MIU/m<span class="Sup">2</span><br>TIW<br></span></th>
</tr>
<tr class="Botrule Last">
<th class="Lrule" align="left">Laboratory Tests</th>
<th align="center">N=143</th>
<th align="center">N=135</th>
<th align="center">N=145</th>
<th align="center">N=352</th>
<th align="center">N=69-73</th>
<th align="center">N=26-28</th>
<th align="center">N=140-171</th>
<th align="center">N=96-101</th>
<th align="center">N=75-103</th>
<th class="Rrule" align="center">N=113-115</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="11">NA — Not Applicable — Patients' initial hematologic laboratory test values were abnormal due to their condition.</td></tr>
<tr><td colspan="11" align="left"><dl class="Footnote">
<dt><a name="footnote-24" href="#footnote-reference-24">*</a></dt>
<dd>Decrease of ≥2 g/dL; 20% 2-&lt;3 g/dL; 6% ≥3 g/dL </dd>
<dt><a name="footnote-25" href="#footnote-reference-25">†</a></dt>
<dd>Decrease of ≥2 g/dL</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">‡</a></dt>
<dd>Decrease of ≥2 g/dL; 14% 2-&lt;3 g/dL; 3% ≥3 g/dL</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">§</a></dt>
<dd>White Blood Cell Count was reported as <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></dd>
<dt><a name="footnote-28" href="#footnote-reference-28">¶</a></dt>
<dd>Decrease to &lt;3000/mm<span class="Sup">3</span>
</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">#</a></dt>
<dd>Decrease to &lt;70,000/mm<span class="Sup">3</span>
</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">Þ</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> plus bands</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">Hemoglobin</td>
<td align="center">22</td>
<td align="center">8</td>
<td align="center">NA</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">15</td>
<td align="center">26<a name="footnote-reference-24" href="#footnote-24" class="Sup">*</a>
</td>
<td align="center">32<a name="footnote-reference-25" href="#footnote-25" class="Sup">†</a>
</td>
<td align="center">23<a href="#footnote-25" class="Sup">†</a>
</td>
<td align="center">17<a name="footnote-reference-26" href="#footnote-26" class="Sup">‡</a>
</td>
</tr>
<tr>
<td align="left">White Blood Cell Count</td>
<td align="center"><a name="footnote-reference-27" href="#footnote-27" class="Sup">§</a></td>
<td align="center">--</td>
<td align="center">NA</td>
<td align="center">17</td>
<td align="center">10</td>
<td align="center">22</td>
<td align="center">26<a name="footnote-reference-28" href="#footnote-28" class="Sup">¶</a>
</td>
<td align="center">68<a href="#footnote-28" class="Sup">¶</a>
</td>
<td align="center">34<a href="#footnote-28" class="Sup">¶</a>
</td>
<td align="center">9<a href="#footnote-28" class="Sup">¶</a>
</td>
</tr>
<tr>
<td align="left">Platelet Count</td>
<td align="center">15</td>
<td align="center">13</td>
<td align="center">NA</td>
<td align="center">--</td>
<td align="center">0</td>
<td align="center">8</td>
<td align="center">15<a name="footnote-reference-29" href="#footnote-29" class="Sup">#</a>
</td>
<td align="center">12<a href="#footnote-29" class="Sup">#</a>
</td>
<td align="center">5<a href="#footnote-29" class="Sup">#</a>
</td>
<td align="center">1<a href="#footnote-29" class="Sup">#</a>
</td>
</tr>
<tr>
<td align="left">Serum Creatinine</td>
<td align="center">3</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">6</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">Alkaline Phosphatase</td>
<td align="center">13</td>
<td align="center">--</td>
<td align="center">4</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">8</td>
<td align="center">4</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">Lactate Dehydrogenase</td>
<td align="center">1</td>
<td align="center">--</td>
<td align="center">0</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">Serum Urea Nitrogen</td>
<td align="center">12</td>
<td align="center">4</td>
<td align="center">0</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span></td>
<td align="center">63</td>
<td align="center">24</td>
<td align="center">4</td>
<td align="center">12</td>
<td align="center">11</td>
<td align="center">41</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">SGPT</td>
<td align="center">2</td>
<td align="center">--</td>
<td align="center">13</td>
<td align="center">--</td>
<td align="center">10</td>
<td align="center">15</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left">Granulocyte Count</td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><ul><li>Total</li></ul></td>
<td align="center">92</td>
<td align="center">36</td>
<td align="center">NA</td>
<td align="center">--</td>
<td align="center">31</td>
<td align="center">39</td>
<td align="center">45<a name="footnote-reference-30" href="#footnote-30" class="Sup">Þ</a>
</td>
<td align="center">75<a href="#footnote-30" class="Sup">Þ</a>
</td>
<td align="center">61<a href="#footnote-30" class="Sup">Þ</a>
</td>
<td align="center">70<a href="#footnote-30" class="Sup">Þ</a>
</td>
</tr>
<tr>
<td align="left"><ul><li>1000-&lt;1500/mm<span class="Sup">3</span>
</li></ul></td>
<td align="center">66</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">32</td>
<td align="center">30</td>
<td align="center">32</td>
<td align="center">43</td>
</tr>
<tr>
<td align="left"><ul><li>750-&lt;1000/mm<span class="Sup">3</span>
</li></ul></td>
<td align="center">--</td>
<td align="center">21</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">10</td>
<td align="center">24</td>
<td align="center">18</td>
<td align="center">18</td>
</tr>
<tr>
<td align="left"><ul><li>500-&lt;750/mm<span class="Sup">3</span>
</li></ul></td>
<td align="center">25</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">1</td>
<td align="center">17</td>
<td align="center">9</td>
<td align="center">7</td>
</tr>
<tr class="Last">
<td align="left"><ul><li>&lt;500/mm<span class="Sup">3</span>
</li></ul></td>
<td align="center">1</td>
<td align="center">13</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.11"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of INTRON A alone or in combination with REBETOL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Blood and Lymphatic System Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> (concurrent <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>), <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span></p>
<p><span class="Italics">Ear and Labyrinth Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">hypopituitarism</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></p>
<p>Vogt-Koyanagi-Harada syndrome, <span class="product-label-link" type="condition" conceptid="374640" conceptname="Serous retinal detachment">serous retinal detachment</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></p>
<p><span class="Italics">General Disorders and Administration Site Conditions</span></p>
<p>asthenic conditions (including <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>)</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></p>
<p>cases of acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span> or exacerbation of <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span> </p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span></p>
<p><span class="Italics">Psychiatric Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="4024763" conceptname="Homicidal thoughts">homicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> including <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span></p>
<p><span class="Italics">Renal and Urinary Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span></p>
<p><span class="Italics">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="4318393" conceptname="Injection site necrosis">injection site necrosis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is limited experience with overdosage.  Postmarketing surveillance includes reports of patients receiving a single dose as great as 10 times the recommended dose.  In general, the primary effects of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are consistent with the effects seen with therapeutic doses of interferon alfa-2b.  Hepatic enzyme abnormalities, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported with single administration <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> and/or with longer durations of treatment than prescribed (see <span class="Bold"><a href="#adverse">ADVERSE REACTIONS</a></span>).  Toxic effects after ingestion of interferon alfa-2b are not expected because interferons are poorly absorbed orally.  Consultation with a poison center is recommended.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">There is no specific antidote for interferon alfa-2b.  Hemodialysis and peritoneal dialysis are not considered effective for treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="doseadmin"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="DA_General"></a><a name="section-10.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="Bold"><span class="Italics">IMPORTANT:</span>  INTRON<span class="Sup">®</span> A</span> is supplied as 1) Powder for Injection/Reconstitution; 2) Solution for Injection in Vials. <span class="Bold">Not all dosage forms and strengths are appropriate for some indications.</span> It is important that you carefully read the instructions below for the indication you are treating to ensure you are using an appropriate dosage form and strength.</p>
<p>To enhance the tolerability of INTRON A, injections should be administered in the evening when possible.</p>
<p>To reduce the incidence of certain adverse reactions, acetaminophen may be administered at the time of injection.</p>
<p>The solution should be allowed to come to room temperature before using.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">Hairy Cell Leukemia</span></h2>
<p class="First"><span class="Bold">(</span>see <span class="Bold"><a href="#DA_General">DOSAGE AND ADMINISTRATION, General</a></span><span class="Bold">)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.1"></a><p></p>
<h3>Dose</h3>
<p class="First"> The recommended dose for the treatment of <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> is 2 million IU/m<span class="Sup">2 </span>administered intramuscularly or subcutaneously 3 times a week for up to 6 months. Patients with platelet counts of less than  50,000/mm<span class="Sup">3</span> should not be administered INTRON A intramuscularly, but instead by subcutaneous administration. Patients who are responding to therapy may benefit from continued treatment.</p>
<table width="85%">
<caption><span>Dosage Forms for This Indication</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage Form</th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Route</th>
<th class="Rrule" align="center">Fixed Doses</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Powder 10 MIU (single dose)</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">IM, SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Solution 18 MIU multidose</td>
<td class="Rrule" align="center">6 MIU/mL</td>
<td class="Rrule" align="center">IM, SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Solution 25 MIU multidose</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">IM, SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
</tbody>
</table>
<p><span class="Bold">NOTE: INTRON A Powder for Injection does not contain a preservative. The vial must be discarded after reconstitution and withdrawal of a single dose.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.2"></a><p></p>
<h3>Dose Adjustment</h3>
<ul class="Disc">
<li>If severe adverse reactions develop, the dosage should be modified (50% reduction) or therapy should be temporarily withheld until the adverse reactions abate and then resume at 50% (1 MIU/m<span class="Sup">2</span> TIW).</li>
<li>If severe adverse reactions persist or recur following dosage adjustment, INTRON A should be permanently discontinued.</li>
<li>INTRON A should be discontinued for progressive disease or failure to respond after six months of treatment. </li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Malignant Melanoma</h2>
<p class="First"><span class="Bold">(</span>see <span class="Bold"><a href="#DA_General">DOSAGE AND ADMINISTRATION, General</a></span><span class="Bold">)</span></p>
<p>INTRON A adjuvant treatment of malignant melanoma is given in two phases, induction and maintenance.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.1"></a><p></p>
<h3>Induction Recommended Dose</h3>
<p class="First">The recommended daily dose of INTRON A in induction is 20 million IU/m<span class="Sup">2</span> as an intravenous infusion, over 20 minutes, 5 consecutive days per week, for 4 weeks (see <span class="Bold Italics"><a href="#Dose_Adjustment">Dose Adjustment</a></span> below).</p>
<table width="60%">
<caption><span>Dosage Forms for This Indication</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage Form</th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Route</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Powder 10 MIU</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">IV</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Powder 18 MIU</td>
<td class="Rrule" align="center">18 MIU/mL</td>
<td class="Rrule" align="center">IV</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Powder 50 MIU</td>
<td class="Rrule" align="center">50 MIU/mL</td>
<td class="Rrule" align="center">IV</td>
</tr>
</tbody>
</table>
<p><span class="Bold">NOTE: INTRON A Solution for Injection in vials is NOT recommended for intravenous administration and should not be used for the induction phase of malignant melanoma.</span></p>
<p><span class="Bold">NOTE: INTRON A Powder for Injection does not contain a preservative. The vial must be discarded after reconstitution and withdrawal of a single dose.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Dose_Adjustment"></a><a name="section-10.3.2"></a><p></p>
<h3>Dose Adjustment</h3>
<p class="First"><span class="Bold">NOTE:</span> Regular laboratory testing should be performed to monitor laboratory abnormalities for the purpose of dose modifications (see <span class="Bold"><a href="#labtest">PRECAUTIONS, Laboratory Tests</a></span>).</p>
<ul class="Disc">
<li>INTRON A should be withheld for severe adverse reactions, including granulocyte counts greater than 250/mm<span class="Sup">3</span> but less than 500/mm<span class="Sup">3</span> or SGPT/<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> greater than 5-10× upper limit of normal, until adverse reactions abate. INTRON A treatment should be restarted at 50% of the previous dose.</li>
<li>INTRON A should be permanently discontinued for:<ul class="Circle">
<li>Toxicity that does not abate after withholding INTRON A</li>
<li>Severe adverse reactions which recur in patients receiving reduced doses of INTRON A</li>
<li>Granulocyte count less than 250/mm<span class="Sup">3</span> or SGPT/<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> of greater than 10× upper limit of normal</li>
</ul>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.3"></a><p></p>
<h3>Maintenance Recommended Dose</h3>
<p class="First">The recommended dose of INTRON A for maintenance is 10 million IU/m<span class="Sup">2</span> as a subcutaneous injection three times per week for 48 weeks (see <span class="Bold Italics"><a href="#Dose_Adjustment_Maintenance">Dose Adjustment</a></span> below).</p>
<table width="85%">
<caption><span>Dosage Forms for This Indication</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage Form</th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Route</th>
<th class="Rrule" align="center">Fixed Doses</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-31" href="#footnote-reference-31">*</a></dt>
<dd>Patients receiving 50% dose reduction only</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">†</a></dt>
<dd>Patients receiving full dose only</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Powder 10 MIU (single dose)<a name="footnote-reference-31" href="#footnote-31" class="Sup">*</a>
</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Powder 18 MIU (single dose)<a name="footnote-reference-32" href="#footnote-32" class="Sup">†</a>
</td>
<td class="Rrule" align="center">18 MIU/mL</td>
<td class="Rrule" align="center">SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Solution 18 MIU multidose</td>
<td class="Rrule" align="center">6 MIU/mL</td>
<td class="Rrule" align="center">SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Solution 25 MIU multidose</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
</tbody>
</table>
<p><span class="Bold">NOTE: INTRON A Powder for Injection does not contain a preservative. The vial must be discarded after reconstitution and withdrawal of a single dose.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Dose_Adjustment_Maintenance"></a><a name="section-10.3.4"></a><p></p>
<h3>Dose Adjustment</h3>
<p class="First"><span class="Bold">NOTE:</span> Regular laboratory testing should be performed to monitor laboratory abnormalities for the purpose of dose modifications (see <span class="Bold"><a href="#labtest">PRECAUTIONS, Laboratory Tests</a></span>).</p>
<ul class="Disc">
<li>INTRON A should be withheld for severe adverse reactions, including granulocyte counts greater than 250/mm<span class="Sup">3</span> but less than 500/mm<span class="Sup">3</span> or SGPT/<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> greater than 5-10× upper limit of normal, until adverse reactions abate. INTRON A treatment should be restarted at 50% of the previous dose.</li>
<li>INTRON A should be permanently discontinued for:<ul class="Circle">
<li>Toxicity that does not abate after withholding INTRON A</li>
<li>Severe adverse reactions which recur in patients receiving reduced doses of INTRON A</li>
<li>Granulocyte count less than 250/mm<span class="Sup">3</span> or SGPT/<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> of greater than 10× upper limit of normal </li>
</ul>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2>Follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">									(see <span class="Bold"><a href="#DA_General">DOSAGE AND ADMINISTRATION, General</a></span><span class="Bold">)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4.1"></a><p></p>
<h3>Dose</h3>
<p class="First">The recommended dose of INTRON A for the treatment of follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> is 5 million IU subcutaneously three times per week for up to 18 months in conjunction with anthracycline-containing chemotherapy regimen and following completion of the chemotherapy regimen.</p>
<table width="85%">
<caption><span>Dosage Forms for This Indication</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage Form</th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Route</th>
<th class="Rrule" align="center">Fixed Doses</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Powder 10 MIU (single dose)</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Solution 18 MIU multidose</td>
<td class="Rrule" align="center">6 MIU/mL</td>
<td class="Rrule" align="center">SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Solution 25 MIU multidose</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
</tbody>
</table>
<p><span class="Bold">NOTE: INTRON A Powder for Injection does not contain a preservative. The vial must be discarded after reconstitution and withdrawal of a single dose.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4.2"></a><p></p>
<h3>Dose Adjustment</h3>
<ul class="Disc">
<li>Doses of myelosuppressive drugs were reduced by 25% from a full-dose CHOP regimen, and cycle length increased by 33% (e.g., from 21 to 28 days) when alpha interferon was added to the regimen.</li>
<li>Delay chemotherapy cycle if neutrophil count was less than 1500/mm<span class="Sup">3</span> or platelet count was less than 75,000/mm<span class="Sup">3</span>.</li>
<li>INTRON A should be permanently discontinued if <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> exceeds greater than 5× the upper limit of normal or serum creatinine greater than 2.0 mg/dL (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</li>
<li>Administration of INTRON A therapy should be withheld for a neutrophil count less than 1000/mm<span class="Sup">3</span>, or a platelet count less than 50,000/mm<span class="Sup">3</span>.</li>
<li>INTRON A dose should be reduced by 50% (2.5 MIU TIW) for a neutrophil count greater than 1000/mm<span class="Sup">3</span>, but less than 1500/mm<span class="Sup">3</span>. The INTRON A dose may be re-escalated to the starting dose (5 million IU TIW) after resolution of hematologic toxicity (ANC greater than 1500/mm<span class="Sup">3</span>).</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5"></a><p></p>
<h2>Condylomata Acuminata</h2>
<p class="First">									(see <span class="Bold"><a href="#DA_General">DOSAGE AND ADMINISTRATION, General</a></span><span class="Bold">)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.1"></a><p></p>
<h3>Dose</h3>
<p class="First">The recommended dose is 1.0 million IU per lesion in a maximum of 5 lesions in a single course. The lesions should be injected three times weekly on alternate days for 3 weeks. An additional course may be administered at 12 to 16 weeks.</p>
<table width="60%">
<caption><span>Dosage Forms for This Indication</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage Form</th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Route</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Powder 10 MIU (single dose)</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">IL</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Solution 25 MIU multidose</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">IL</td>
</tr>
</tbody>
</table>
<p><span class="Bold">NOTE: INTRON A Powder for Injection does not contain a preservative. The vial must be discarded after reconstitution and withdrawal of a single dose.</span></p>
<p><span class="Bold">NOTE: Do not use the following formulations for this indication:</span></p>
<ul class="Disc">
<li><span class="Bold">the 18 million or 50 million IU Powder for Injection</span></li>
<li><span class="Bold">the 18 million IU multidose INTRON A Solution for Injection</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.2"></a><p></p>
<h3>Dose Adjustment</h3>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.3"></a><p></p>
<h3>Technique for Injection</h3>
<p class="First">The injection should be administered intralesionally using a Tuberculin or similar syringe and a 25- to 30-gauge needle. The needle should be directed at the center of the base of the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">wart</span> and at an angle almost parallel to the plane of the skin (approximately that in the commonly used PPD test). This will deliver the interferon to the dermal core of the lesion, infiltrating the lesion and causing a small wheal. Care should be taken not to go beneath the lesion too deeply; subcutaneous injection should be avoided, since this area is below the base of the lesion. Do not inject too superficially since this will result in possible leakage, infiltrating only the keratinized layer and not the dermal core.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.6"></a><p></p>
<h2>AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span> </h2>
<p class="First">									(see <span class="Bold"><a href="#DA_General">DOSAGE AND ADMINISTRATION, General</a></span><span class="Bold">)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.6.1"></a><p></p>
<h3>Dose</h3>
<p class="First">The recommended dose of INTRON A for Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span> is 30 million IU/m<span class="Sup">2</span>/dose administered subcutaneously or intramuscularly three times a week until disease progression or maximal response has been achieved after 16 weeks of treatment. Dose reduction is frequently required (see <span class="Bold Italics"><a href="#Dose_Adjustment_Sarcoma">Dose Adjustment</a></span> below).</p>
<table width="60%">
<caption><span>Dosage Forms for This Indication</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage Form</th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Route</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left">Powder 50 MIU</td>
<td class="Rrule" align="center">50 MIU/mL</td>
<td class="Rrule" align="center">IM, SC</td>
</tr></tbody>
</table>
<p><span class="Bold">NOTE: INTRON A Solution for Injection in vials should NOT be used for AIDS-Related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span>.</span></p>
<p><span class="Bold">NOTE: INTRON A Powder for Injection does not contain a preservative. The vial must be discarded after reconstitution and withdrawal of a single dose.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Dose_Adjustment_Sarcoma"></a><a name="section-10.6.2"></a><p></p>
<h3>Dose Adjustment</h3>
<ul class="Disc">
<li>INTRON A dose should be reduced by 50% or withheld for severe adverse reactions.</li>
<li>INTRON A may be resumed at a reduced dose if severe adverse reactions abate with interruption of dosing.</li>
<li>INTRON A should be permanently discontinued if severe adverse reactions persist or if they recur in patients receiving a reduced dose.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span></h2>
<p class="First">(see <span class="Bold"><a href="#DA_General">DOSAGE AND ADMINISTRATION, General</a></span>)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.7.1"></a><p></p>
<h3>Dose</h3>
<p class="First">The recommended dose of INTRON A for the treatment of <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">chronic hepatitis C</span> is 3 million IU three times a week (TIW) administered subcutaneously or intramuscularly. In patients tolerating therapy with normalization of ALT at 16 weeks of treatment, INTRON A therapy should be extended to 18 to 24 months (72 to 96 weeks) at 3 million IU TIW to improve the sustained response rate (see <span class="Bold"><a href="#CP_Chronic_Hepatitis_C">CLINICAL PHARMACOLOGY, <span class="product-label-link" type="condition" conceptid="198964" conceptname="Chronic hepatitis C">Chronic Hepatitis C</span></a></span>). Patients who do not normalize their ALTs or have persistently high levels of HCV RNA after 16 weeks of therapy rarely achieve a sustained response with extension of treatment. Consideration should be given to discontinuing these patients from therapy.</p>
<p>When INTRON A is administered in combination with REBETOL<span class="Sup">®</span>, patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and/or those over the age of 50 should be carefully monitored with respect to the development of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. See REBETOL prescribing information for dosing when used in combination with REBETOL for adults and pediatric patients.</p>
<table width="85%">
<caption><span>Dosage Forms for This Indication</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage Form</th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Route</th>
<th class="Rrule" align="center">Fixed Doses</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left">Solution 18 MIU multidose</td>
<td class="Rrule" align="center">6 MIU/mL</td>
<td class="Rrule" align="center">IM, SC</td>
<td class="Rrule" align="center">N/A</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.7.2"></a><p></p>
<h3>Dose Adjustment</h3>
<p class="First">If severe adverse reactions develop during INTRON A treatment, the dose should be modified (50% reduction) or therapy should be temporarily discontinued until the adverse reactions abate. If intolerance persists after dose adjustment, INTRON A therapy should be discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B Adults</h2>
<p class="First">(see <span class="Bold"><a href="#DA_General">DOSAGE AND ADMINISTRATION, General</a></span>)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.8.1"></a><p></p>
<h3>Dose</h3>
<p class="First">The recommended dose of INTRON A for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B is 30 to 35 million IU per week, administered subcutaneously or intramuscularly, either as 5 million IU daily (QD) or as 10 million IU three times a week (TIW) for 16 weeks.</p>
<table width="85%">
<caption><span>Dosage Forms for This Indication</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage Form</th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Route</th>
<th class="Rrule" align="center">Fixed Doses</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Powder 10 MIU (single dose)</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">IM, SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Solution 25 MIU multidose</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">IM, SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
</tbody>
</table>
<p><span class="Bold">NOTE: INTRON A Powder for Injection does not contain a preservative. The vial must be discarded after reconstitution and withdrawal of a single dose.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="chbp"></a><a name="section-10.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B Pediatrics</h2>
<p class="First">(see <span class="Bold"><a href="#DA_General">DOSAGE AND ADMINISTRATION, General</a></span>)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.9.1"></a><p></p>
<h3>Dose</h3>
<p class="First">The recommended dose of INTRON A for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B is 3 million IU/m<span class="Sup">2 </span>three times a week (TIW) for the first week of therapy followed by dose escalation to 6 million IU/m<span class="Sup">2</span> TIW (maximum of 10 million IU TIW) administered subcutaneously for a total duration of 16 to 24 weeks.</p>
<table width="85%">
<caption><span>Dosage Forms for This Indication</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Dosage Form</th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Route</th>
<th class="Rrule" align="center">Fixed Doses</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Powder 10 MIU (single dose)</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Solution 25 MIU multidose</td>
<td class="Rrule" align="center">10 MIU/mL</td>
<td class="Rrule" align="center">SC</td>
<td class="Rrule" align="center">N/A</td>
</tr>
</tbody>
</table>
<p><span class="Bold">NOTE: INTRON A Powder for Injection does not contain a preservative. The vial must be discarded after reconstitution and withdrawal of a single dose.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.9.2"></a><p></p>
<h3>Dose Adjustment</h3>
<p class="First">If severe adverse reactions or laboratory abnormalities develop during INTRON A therapy, the dose should be modified (50% reduction) or discontinued if appropriate, until the adverse reactions abate. If intolerance persists after dose adjustment, INTRON A therapy should be discontinued.</p>
<p>For patients with decreases in white blood cell, granulocyte or platelet counts, the following guidelines for dose modification should be followed:</p>
<a name="guidelines"></a><table width="85%">
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">INTRON A Dose</th>
<th class="Rrule" align="center">White Blood Cell Count</th>
<th class="Rrule" align="center">Granulocyte Count</th>
<th class="Rrule" align="center">Platelet Count</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Reduce 50%</td>
<td class="Rrule" align="center">&lt;1.5 × 10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">&lt;0.75 × 10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">&lt;50 × 10<span class="Sup">9</span>/L</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Permanently Discontinue</td>
<td class="Rrule" align="center">&lt;1.0 × 10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">&lt;0.5 × 10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">&lt;25 × 10<span class="Sup">9</span>/L</td>
</tr>
</tbody>
</table>
<p>INTRON A therapy was resumed at up to 100% of the initial dose when white blood cell, granulocyte, and/or platelet counts returned to normal or baseline values.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>PREPARATION AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Reconstitution of INTRON<span class="Sup">®</span> A Powder for Injection</h2>
<p class="First">Reconstitute INTRON A Powder for Injection with 1 mL of Sterile Water for Injection, USP. The Sterile Water for Injection supplied contains 5 mL and is intended for single use. Discard the unused portion. The reconstituted solution is clear and colorless to light yellow. The INTRON A powder reconstituted with Sterile Water for Injection USP is a single-use vial and does not contain a preservative. <span class="Bold">DO NOT RE-ENTER VIAL AFTER WITHDRAWING THE DOSE.  DISCARD UNUSED PORTION</span> (see <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>).  Once the dose from the single-dose vial has been withdrawn, the <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of any remaining product can no longer be guaranteed.  Pooling of unused portions of some medications has been linked to bacterial contamination and morbidity.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1"></a><p></p>
<h3>•   Intramuscular, Subcutaneous, or Intralesional Administration</h3>
<p class="First">Inject 1 mL Diluent (Sterile Water for Injection USP) for INTRON A into the INTRON A vial.  Swirl gently to hasten complete dissolution of the powder.  The appropriate INTRON A dose should then be withdrawn and injected intramuscularly, subcutaneously, or intralesionally (see <span class="Bold"><a href="#mg">MEDICATION GUIDE</a></span> and <span class="Bold"><a href="#ifu-powder">Instructions for Use</a></span> for detailed instructions).</p>
<p>Please refer to the <span class="Bold">MEDICATION GUIDE</span> and <span class="Bold">Instructions for Use</span> for detailed, step-by-step instructions on how to inject the INTRON A dose.  After preparation and administration of the INTRON A injection, it is essential to follow the procedure for proper disposal of syringes and needles (see <span class="Bold"><a href="#mg">MEDICATION GUIDE</a></span> and <span class="Bold"><a href="#ifu-powder">Instructions for Use</a></span> for detailed instructions).</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.2"></a><p></p>
<h3>•   Intravenous Infusion</h3>
<p class="First">The infusion solution should be prepared immediately prior to use.  Based on the desired dose, the appropriate vial strength(s) of INTRON A should be reconstituted with the diluent provided.  Inject 1 mL Diluent (Sterile Water for Injection USP) for INTRON A into the INTRON A vial.  Swirl gently to hasten complete dissolution of the powder.  The appropriate INTRON A dose should then be withdrawn and injected into a 100-mL bag of 0.9% Sodium Chloride Injection USP.  The final concentration of INTRON A should not be less than 10 million IU/100 mL.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>INTRON A Solution for Injection in Vials</h2>
<p class="First">INTRON A Solution for Injection is supplied in two multidose vials.  The solutions for injection do not require reconstitution prior to administration; the solution is clear and colorless.</p>
<p>The appropriate dose should be withdrawn from the vial and injected intramuscularly, subcutaneously, or intralesionally.</p>
<p><span class="Bold">INTRON A Solution for Injection is not recommended for intravenous administration.</span></p>
<p>Please refer to the <span class="Bold"><a href="#mg">MEDICATION GUIDE</a></span> and <span class="Bold"><a href="#ifu-solution">Instructions for Use</a></span> for detailed, step-by-step instructions on how to inject the INTRON A dose.  After preparation and administration of INTRON A, it is essential to follow the procedure for proper disposal of syringes and needles.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2>INTRON<span class="Sup">®</span> A Powder for Injection</h2>
<p class="First">INTRON A Powder for Injection, 10 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4350-01).</p>
<p>INTRON A Powder for Injection, 18 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 vial of INTRON A and 1 vial of INTRON A Diluent (NDC 0085-4351-01).</p>
<p>INTRON A Powder for Injection, 50 million IU per vial and Diluent for INTRON A (Sterile Water for Injection USP) 5 mL per vial; boxes containing 1 INTRON A vial and 1 vial of INTRON A Diluent (NDC 0085-4352-01).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>INTRON A Solution for Injection in Vials</h2>
<p class="First">INTRON A Solution for Injection, 18 million IU multidose vial (22.8 million IU per 3.8 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1168-01).</p>
<p>INTRON A Solution for Injection, 25 million IU multidose vial (32 million IU per 3.2 mL per vial); boxes containing 1 vial of INTRON A Solution for Injection (NDC 0085-1133-01).</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.3"></a><p></p>
<h2>Storage</h2>
<ul class="Disc">
<li>
<span class="Bold">INTRON A Powder for Injection/Reconstitution</span><br> INTRON A Powder for Injection should be stored in the refrigerator at 2° to 8°C (36°-46°F). After reconstitution, the solution should be used immediately, but may be stored up to 24 hours at 2° to 8°C (36°-46°F). Throw away any medicine left in the vial after you withdraw 1 dose.</li>
<li>
<span class="Bold">INTRON A Solution for Injection in Vials</span><br> INTRON A Solution for Injection in vials should be stored in the refrigerator at 2° to 8°C (36°-46°F).<br>INTRON A Solution for Injection should not be frozen and should be kept away from heat.  Throw away any unused INTRON A Solution for Injection remaining in the vial after one month.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>References</h1>
<ol class="Arabic">
<li>Smalley R, et al. <span class="Italics">N Engl J Med.</span> 1992;327:1336-1341.</li>
<li>Aviles A, et al. <span class="Italics"><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span>.</span> 1996;20:495-499.</li>
<li>Unterhalt M, et al. <span class="Italics">Blood.</span> 1996;88(10 Suppl 1):1744A.</li>
<li>Schiller J, et al. <span class="Italics">J Biol Response Mod.</span> 1989;8:252-261.</li>
<li>Poynard T, et al. <span class="Italics">N Engl J Med.</span> 1995;332(22)1457-1462.</li>
<li>Lin R, et al. <span class="Italics">J Hepatol.</span> 1995;23:487-496.</li>
<li>Perrillo R, et al. <span class="Italics">N Engl J Med.</span> 1990;323:295-301.</li>
<li>Perez V, et al. <span class="Italics">J Hepatol.</span> 1990;11:S113-S117.</li>
<li>Knodell R, et al. <span class="Italics">Hepatology.</span> 1981;1:431-435.</li>
<li>Perrillo R, et al. <span class="Italics">Ann Intern Med.</span> 1991;115:113-115.</li>
<li>Kauppila A, et al. <span class="Italics">Int J Cancer.</span> 1982;29:291-294.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured by: Schering Corporation, a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC. </span><br>Whitehouse Station, NJ 08889, USA</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright <span class="Sup">©</span> 1986, 2011 Schering Corporation, a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span> All rights reserved.</p>
<p>Rev. 05/2015</p>
<p>uspi-mk2958-mtl-5ml-1505r001</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="mg"></a><a name="section-15"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">INTRON<span class="Sup">®</span> A</span> (In-tron-aye)<br><span class="Bold">(Interferon alfa-2b, recombinant)</span></p>
<p>Read this Medication Guide before you start taking INTRON A, and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">If you are taking INTRON A with REBETOL, also read the Medication Guide for REBETOL<span class="Sup">®</span> (ribavirin) Capsules and Oral Solution.</span></p>
<p>INTRON A alone is a treatment for certain types of cancers and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus. INTRON A by itself or with REBETOL is a treatment for some people infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus.</p>
<p><a name="What_is_most_important_info"></a><span class="Bold">What is the most important information I should know about INTRON A?</span></p>
<p><span class="Bold">INTRON A can cause serious side effects that:</span></p>
<ul class="Disc">
<li><span class="Bold">may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, or</span></li>
<li><span class="Bold">may worsen certain serious diseases that you may already have.</span></li>
</ul>
<p><span class="Bold">Tell your healthcare provider right away if you have any of the symptoms listed below while taking INTRON A. If symptoms get worse, or become severe and continue, your healthcare provider may tell you to stop taking INTRON A permanently.  In many, but not all people, these symptoms go away after they stop taking INTRON A.</span></p>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">Heart problems</span>. Some people who take INTRON A may develop heart problems, including:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></li>
<li>fast heart rate or abnormal heart beats</li>
<li>trouble breathing or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> or heart muscle problems (<span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>)</li>
</ul>
</dd>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or symptoms of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Symptoms may include <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, loss of coordination, and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>.</span> <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or symptoms of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> may happen in people who have some risk factors <span class="Bold">or</span> no known risk factors for a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</dd>
<dt class="Bold">3.</dt>
<dd>
<span class="Bold">Mental health problems, including <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</span> INTRON A may cause you to develop mood or behavior problems that may get worse during treatment with INTRON A or after your last dose, including:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> (getting upset easily)</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (feeling low, feeling bad about yourself, or feeling hopeless) </li>
<li>acting aggressive, being angry or violent</li>
<li>thoughts of hurting yourself or others, or <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>former drug addicts may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> back into <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span> or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> </li>
</ul> If you have these symptoms, your healthcare provider should carefully monitor you during treatment with INTRON A and for 6 months after your last dose.</dd>
<dt class="Bold">4.</dt>
<dd>
<span class="Bold">New or worsening autoimmune disease</span>. Some people taking INTRON A develop autoimmune diseases (a condition where the body's immune cells attack other cells or organs in the body), including <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>, and <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. In some people who already have an autoimmune disease, the disease may get worse while on INTRON A.</dd>
<dt class="Bold">5.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>.</span> Some people who take INTRON A may get an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Symptoms may include:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span></li>
<li>burning or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with urination</li>
<li>urinating often</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up mucus (<span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">phlegm</span>) that is discolored (for example yellow or pink)</li>
</ul>
</dd>
</dl>
<p>While taking INTRON A, you should see a healthcare provider regularly for check-ups and blood tests to make sure that your treatment is working and to check for side effects.</p>
<p><span class="Bold">What is INTRON A?</span></p>
<p>INTRON A is a prescription medicine that is used:</p>
<ul class="Disc">
<li>to treat adults with a blood cancer called <span class="product-label-link" type="condition" conceptid="4038845" conceptname="Hairy cell leukemia">hairy cell leukemia</span> </li>
<li>to treat certain adults with a type of skin cancer called malignant melanoma</li>
<li>to treat adults with some types of Follicular Non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> along with certain chemotherapy medicines</li>
<li>to treat certain adults with <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span> (condylomata acuminate), by injecting the medicine directly into the <span class="product-label-link" type="condition" conceptid="140641" conceptname="Verruca vulgaris">warts</span></li>
<li>to treat certain adults with a type of cancer caused by AIDS, called AIDS-related Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcoma</span></li>
<li>alone to treat adults with chronic (lasting a long time) <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with stable liver problems</li>
<li>with REBETOL to treat chronic (lasting a long time) <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in people 3 years and older with stable liver problems</li>
<li>to treat chronic (lasting a long time) <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in people 1 year and older with stable liver problems</li>
</ul>
<p><span class="Bold">Who should not take INTRON A?</span></p>
<p>Do not take INTRON A if you:</p>
<ul class="Disc">
<li>had a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to another alpha interferon product or are allergic to any of the ingredients in INTRON A. See the end of this Medication Guide for a complete list of ingredients. Ask your healthcare provider if you are not sure.</li>
<li>have certain types of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (<span class="product-label-link" type="condition" conceptid="200762" conceptname="Autoimmune hepatitis">autoimmune hepatitis</span>)</li>
<li>have certain other liver problems</li>
</ul>
<p>Talk to your healthcare provider before taking INTRON A if you have any of these conditions.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking INTRON A?</span></p>
<p><span class="Bold">Before you take INTRON A,</span> tell your healthcare provider if you:</p>
<ul class="Disc">
<li><span class="Bold">See "<a href="#What_is_most_important_info">What is the most important information I should know about INTRON A?</a>"</span></li>
<li>have or ever had any problems with your heart, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or have high blood pressure</li>
<li>have or ever had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems or blood clots</li>
<li>are being treated for a mental illness or had treatment in the past for any mental illness, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and thoughts of hurting yourself or others</li>
<li>have any kind of autoimmune disease (where the body's immune system attacks the body's own cells), such as <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span></li>
<li>have or ever had low blood cell counts</li>
<li>have ever been addicted to drugs or alcohol</li>
<li>have cirrhosis or other liver problems (other than <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C)</li>
<li>have or had lung problems, such as <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>)</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>have <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of your intestine)</li>
<li>have a condition that suppresses your immune system, such as cancer</li>
<li>have <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li>have <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (the virus that causes AIDS) </li>
<li>have kidney problems</li>
<li>have high blood triglyceride levels (fat in your blood)</li>
<li>have an organ transplant and are taking medicine that keeps your body from rejecting your transplant (suppresses your immune system)</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. It is not known if INTRON A will harm your unborn baby. You should use effective birth control during treatment with INTRON A. Talk to your healthcare provider about birth control choices for you during treatment with INTRON A. Tell your healthcare provider if you become pregnant during treatment with INTRON A.</li>
<li>are breast-feeding or plan to breast-feed. It is not known if INTRON A passes into your breast milk. You and your healthcare provider should decide if you will use INTRON A or breast-feed. You should not do both.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. INTRON A and certain other medicines may affect each other and cause side effects.</p>
<p><span class="Bold">Especially tell your healthcare provider if you take:</span></p>
<ul class="Disc">
<li>the anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B medicine telbivudine (Tyzeka) </li>
<li>the anti-HIV medicine zidovudine (Retrovir) </li>
<li>theophylline (Theo-24, Elixophyllin, Uniphyl, Theolair). Your healthcare provider may need to monitor the amount of theophylline in your body and make changes to your theophylline dose. </li>
</ul>
<p><span class="Bold">Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.</span></p>
<p><span class="Bold">How should I take INTRON A?</span></p>
<ul class="Disc">
<li>INTRON A is given as an injection under the skin (subcutaneous) or into a muscle (intramuscular), into genital lesions, or as an injection into a vein (intravenous), depending on the condition that is being treated.</li>
<li>Your healthcare provider will decide your dose of INTRON A and how often you will take it. </li>
<li>If your healthcare provider decides that you can inject INTRON A for your condition, inject it exactly as prescribed, under your skin (subcutaneous injection) or into your muscle (intramuscular injection). Do not change your dose or how you inject INTRON A unless your healthcare provider tells you to.</li>
<li>Do not take more than your prescribed dose.</li>
<li>Your healthcare provider should show you how to prepare and measure your dose of INTRON A and how to inject yourself before you use INTRON A for the first time.</li>
<li>You should not inject INTRON A until your healthcare provider has shown you how to use INTRON A the right way.</li>
<li>INTRON A comes as:<ul class="Disc">
<li>a powder for injection in a vial that is used only 1 time (single-use vial). The powder must be mixed with water for injection (a diluent) before you inject it. </li>
<li>a solution for injection in a multi-dose vial </li>
</ul>
</li>
<li>See the attached <a href="#ifu-solution">Instructions for Use</a> for detailed instructions for preparing and injecting a dose of INTRON A.</li>
<li>If you miss a dose of INTRON A, take the missed dose as soon as possible during the same day or the next day, then continue on your regular dosing schedule. If several days go by after you miss a dose, check with your healthcare provider to see what to do. </li>
<li>Do not inject more than 1 dose or take more than your prescribed dose without talking to your healthcare provider. </li>
<li>If you take too much INTRON A, call your healthcare provider right away. Your healthcare provider may examine you more closely, and do blood tests. </li>
<li>Your healthcare provider should do blood tests before you start INTRON A, and regularly during your treatment to see how well the treatment is working and to check for side effects. </li>
</ul>
<p><span class="Bold">What are the possible side effects of INTRON A?</span></p>
<p><span class="Bold">INTRON A may cause serious side effects including:</span></p>
<ul class="Disc">
<li><span class="Bold">See "<a href="#What_is_most_important_info">What is the most important information I should know about INTRON A?</a>"</span></li>
<li>
<span class="Bold">Blood problems.</span> INTRON A can affect your bone marrow and cause low white blood cell and platelet counts. In some people, these blood counts may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> to dangerously low levels. If your blood cell counts become very low, you can get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or have <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems.</li>
<li>
<span class="Bold">Serious eye problems.</span> INTRON A may cause eye problems that may lead to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>. You should have an eye exam before you start taking INTRON A. If you have eye problems or have had them in the past, you may need eye exams while taking INTRON A. Tell your healthcare provider or eye doctor right away if you have any vision changes while taking INTRON A.</li>
<li>
<span class="Bold">Thyroid problems.</span> Some people develop changes in the function of their thyroid. Symptoms of thyroid problems include:<ul class="Circle">
<li>problems concentrating</li>
<li><span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">feeling cold</span> or hot all the time</li>
<li>changes in your weight</li>
<li>skin changes </li>
</ul>
</li>
<li>
<span class="Bold">Blood sugar problems</span>. Some people may develop high blood sugar or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. If you have high blood sugar or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> before starting INTRON A, talk to your healthcare provider before you take INTRON A. If you develop high blood sugar or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> while taking INTRON A, your healthcare provider may tell you to stop INTRON A and prescribe a different medicine for you. Symptoms of high blood sugar or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> may include:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li>urinating more often than normal</li>
<li><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
<li>your breath smells like fruit</li>
</ul>
</li>
<li>
<span class="Bold">Lung problems including:</span><ul class="Circle">
<li>trouble breathing </li>
<li><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></li>
<li><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of lung tissue</li>
<li>new or worse high blood pressure of the lungs (<span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>). This can be severe and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </li>
</ul>
</li>
</ul>
<dl>
<dt> </dt>
<dd>You may need to have a chest X-ray or other tests if you develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, or other symptoms of a lung problem during treatment with INTRON A.</dd>
</dl>
<ul>
<li>
<span class="Bold">Severe liver problems, or worsening of liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>. Symptoms may include:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>loss of appetite</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>yellowing of your skin or the white part of your eyes</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> more easily than normal</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your stomach area (abdomen)</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></li>
<li>you cannot be awakened (<span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>)</li>
</ul>
</li>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Symptoms may include:</span><table class="Noautorules" width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, lips, tongue, or throat</li>
<li>trouble breathing</li>
<li>anxiousness</li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li>feeling <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, sores in your mouth, or your skin <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and peels</li>
</ul></td>
</tr></tbody>
</table>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of your pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>) and intestines (<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>).</span> Symptoms may include:<ul>
<li>severe stomach area (abdomen) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>severe <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
</ul>
</li>
<li>
<span class="Bold">New or worsening autoimmune disease</span>. Some patients taking INTRON A develop autoimmune diseases (a condition where the body's immune cells attack other cells or organs in the body), including <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>, and <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. In some patients who already have an autoimmune disease, the disease may worsen while on INTRON A. </li>
<li>
<span class="Bold">Nerve problems.</span> People who take INTRON A or other alpha interferon products with telbivudine (Tyzeka) can develop nerve problems such as continuing <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> in the arms or legs (<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>). Call your healthcare provider if you have any of these symptoms.</li>
<li>
<span class="Bold">Growth problems in children. </span><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span> and slowed growth are common in children during combination treatment with INTRON A and REBETOL. Most children will go through a growth spurt and gain weight after treatment stops. Some children may not reach the height that they were expected to have before treatment. Talk to your healthcare provider if you are concerned about your child's growth during treatment with INTRON A and REBETOL.</li>
<li><span class="Bold">Dental and gum problems.</span></li>
</ul>
<p><span class="Bold">Tell your healthcare provider right away if you have any of the symptoms listed above. </span></p>
<p><span class="Bold">The most common side effects of INTRON A include:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Flu-like symptoms</span>. Symptoms may include: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Some of these symptoms may be decreased by injecting your INTRON A dose in the evening. Talk to your healthcare provider about which over-the-counter medicines you can take to help prevent or decrease some of the symptoms. </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Tiredness</span></span>. Many people become very tired during treatment with INTRON A. </li>
<li>
<span class="Bold">Appetite problems.</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, loss of appetite, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> can happen with INTRON A. </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span></span>. <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> are common at the injection site. </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair thinning</span></span>. </li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the side effects of INTRON A. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1–800–FDA–1088.</p>
<p><span class="Bold">How should I store INTRON A? </span></p>
<p><span class="Bold">INTRON A Solution for Injection</span>:</p>
<ul class="Circle">
<li>Store in the refrigerator between 36°F to 46°F (2°C to 8°C).</li>
<li>INTRON A Solution for Injection in Multidose vials for injection may be used to give more than 1 injection of medicine.</li>
<li>Do not freeze.</li>
<li>Throw away any unused INTRON A Solution for Injection remaining in the vial after one month.</li>
</ul>
<p><span class="Bold">INTRON A Powder for Injection</span>:</p>
<p>Before mixing, store in the refrigerator between 36°F to 46°F (2°C to 8°C). </p>
<ul class="Circle">
<li>After mixing the INTRON A Powder for Injection, use the solution right away or store the solution in the refrigerator for up to 24 hours between 36°F to 46°F (2°C to 8°C). </li>
<li>Throw away any medicine left in the vial after you withdraw 1 dose.</li>
<li>Do not freeze.</li>
</ul>
<p><span class="Bold">Keep INTRON A and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General Information about INTRON A</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use INTRON A for a condition for which it was not prescribed. Do not give INTRON A to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about INTRON A. If you would like more information, ask your healthcare provider. You can ask your healthcare provider or pharmacist for information about INTRON A that was written for health care professionals.</p>
<ul class="Circle"><li>For more information, go to www.IntronA.com or call 1<span class="Bold">-</span>800-622-4477. </li></ul>
<p><a name="list_of_ingredients"></a><span class="Bold">What are the ingredients in INTRON A?</span></p>
<p><span class="Bold">Active ingredient:</span> interferon alfa-2b</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<ul class="Circle">
<li>
<span class="Bold">Powder for injection contains</span>: glycine, sodium phosphate dibasic, sodium phosphate monobasic, human albumin. Sterile water for injection is provided as a diluent.</li>
<li>
<span class="Bold">Solution Multidose vials for injection contain</span>: sodium chloride, sodium phosphate dibasic, sodium phosphate monobasic, edetate disodium, polysorbate 80, and m-cresol as a preservative.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">The Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by: Schering Corporation, a subsidiary of <span class="Bold">Merck &amp; Co., Inc.,</span> Whitehouse Station, NJ 08889 USA</p>
<p>Revised: May 2015</p>
<p>Copyright © 1996, 2011 Schering Corporation, a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>usmg-mk2958-mtl-1505r011</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ifu-solution"></a><a name="section-17"></a><p></p>
<h1>Instructions for Use</h1>
<p class="First"><span class="Bold">INTRON<span class="Sup">®</span> A</span> (In-tron-aye)<br><span class="Bold">(Interferon alfa-2b, recombinant)<br>Solution for Injection</span></p>
<p>Be sure that you read, understand and follow these instructions before injecting INTRON A. Your healthcare provider should show you how to prepare, measure and inject INTRON A properly before you use it for the first time. Ask your healthcare provider if you have any questions.</p>
<p>Before starting, collect all of the supplies that you will need to use for preparing and injecting INTRON A. For each injection, you will need the following supplies: </p>
<ul class="Circle">
<li>1 vial of INTRON A solution </li>
<li>1 single-use disposable syringe and needle </li>
<li>1 cotton ball or gauze </li>
<li>2 alcohol swabs </li>
<li>1 sharps disposal container for throwing away (dispose of) your used syringes, needles, and vials. See "<a href="#How_should_I_dispose">How should I dispose of used syringes, needles, and vials?</a>" at the end of this Instructions for Use.</li>
</ul>
<p><span class="Bold">Important:</span></p>
<ul>
<li><span class="Bold">Never re-use disposable syringes and needles. </span></li>
<li>Make sure you have the right syringe and needle to use with INTRON A. Your healthcare provider should tell you what syringes and needles to use to inject INTRON A. </li>
</ul>
<p><span class="Bold">How should I prepare a dose of INTRON<span class="Sup">®</span> A?</span></p>
<dl>
<dt>1</dt>
<dd>Find a well lit, clean, flat working surface.</dd>
<dt>2.</dt>
<dd>Before removing INTRON A from the carton, look at the expiration date printed on the carton. Make sure that the expiration date has not passed. Do not use if the expiration date has passed. </dd>
<dt>3.</dt>
<dd>Wash your hands well with soap and warm water (See <a href="#FigureA_Injection">Figure A</a>). Keep your work area, your hands and injection site clean to decrease the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <div class="Figure">
<a name="FigureA_Injection"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-01.jpg"><p class="MultiMediaCaption">Figure A</p>
</div>
</dd>
<dt>4.</dt>
<dd>Remove 1 vial of INTRON A solution from the carton (See <a href="#FigureB_Injection">Figure B</a>).<div class="Figure">
<a name="FigureB_Injection"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-02.jpg"><p class="MultiMediaCaption">Figure B</p>
</div>
</dd>
<dt>5.</dt>
<dd>Look at the vial of INTRON A. The solution should be clear and colorless, without particles. Do not use the vial of INTRON A if the medicine is cloudy, has particles or is not clear and colorless. </dd>
<dt>6.</dt>
<dd>Remove the protective plastic cap from the top of the INTRON A vial. Clean the rubber stopper on the top of the INTRON A vial with an alcohol swab (See <a href="#FigureC_Injection">Figure C</a>).<div class="Figure">
<a name="FigureC_Injection"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-03.jpg"><p class="MultiMediaCaption">Figure C</p>
</div>
</dd>
<dt>7.</dt>
<dd>Gently warm the INTRON A solution by slowly rolling the vial in the palms of your hands for about one minute (See <a href="#FigureD_Injection">Figure D</a>). Do not shake the vial.<div class="Figure">
<a name="FigureD_Injection"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-04.jpg"><p class="MultiMediaCaption">Figure D</p>
</div>
</dd>
<dt>8.</dt>
<dd>Open the package of the syringe you are using (See <a href="#FigureE_Injection">Figure E</a>) and if it does not have a needle attached, then attach a new needle to the syringe.<div class="Figure">
<a name="FigureE_Injection"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-05.jpg"><p class="MultiMediaCaption">Figure E</p>
</div>
</dd>
<dt>9.</dt>
<dd>Remove the protective cap from the needle of the syringe. Fill the syringe with air by pulling back on the plunger to the mark on the syringe that matches the dose prescribed by your healthcare provider (See <a href="#FigureF_Injection">Figure F</a>).<div class="Figure">
<a name="FigureF_Injection"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-06.jpg"><p class="MultiMediaCaption">Figure F</p>
</div>
</dd>
<dt>10.</dt>
<dd>Hold the vial of INTRON A Solution for Injection on your flat working surface (See <a href="#FigureG_Injection">Figure G</a>). Do not touch the cleaned rubber stopper.<div class="Figure">
<a name="FigureG_Injection"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-07.jpg"><p class="MultiMediaCaption">Figure G</p>
</div>
</dd>
<dt>11.</dt>
<dd>Push the needle straight down through the middle of the rubber stopper of the vial containing the INTRON A solution (See <a href="#FigureH_Injection">Figure H</a>). Slowly inject all the air from the syringe into the air space above the solution.<div class="Figure">
<a name="FigureH_Injection"></a><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-08.jpg"><p class="MultiMediaCaption">Figure H</p>
</div>
</dd>
<dt>12.</dt>
<dd>Keep the needle in the vial. Turn the vial upside down (See <a href="#FigureI_Injection">Figure I</a>). 							<ul class="Circle">
<li>Make sure the tip of the needle is in the INTRON A solution. </li>
<li>Slowly pull the plunger back to fill the syringe with INTRON A solution to the dose (mL or cc) prescribed by your healthcare provider.<div class="Figure">
<a name="FigureI_Injection"></a><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-09.jpg"><p class="MultiMediaCaption">Figure I</p>
</div>
</li>
</ul>
</dd>
<dt>13.</dt>
<dd>With the needle still in the vial, check the syringe for air bubbles (See <a href="#FigureJ_Injection">Figure J</a>).  							<ul class="Circle">
<li>If there are any air bubbles, gently tap the syringe with your finger until the air bubbles rise to the top of the syringe. </li>
<li>Slowly push the plunger up to remove the air bubbles.</li>
<li>If you push solution back into the vial, slowly pull back on the plunger to draw the dose (mL or cc) prescribed by your healthcare provider.<div class="Figure">
<a name="FigureJ_Injection"></a><img alt="Figure J" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-10.jpg"><p class="MultiMediaCaption">Figure J</p>
</div>
</li>
</ul>
</dd>
<dt>14.</dt>
<dd>Do not remove the needle from the vial. Lay the vial and syringe on its side on your flat work surface until you are ready to inject the INTRON A solution.</dd>
</dl>
<p><span class="Bold">How should I choose a site for injection?</span></p>
<p>Based on your treatment, your healthcare provider will tell you if you should inject a dose of INTRON<span class="Bold"><span class="Sup">®</span></span> A under the skin (subcutaneous injection) or into the muscle (intramuscular injection). If it is too difficult for you to inject, ask someone who has been trained to give injections to help you.</p>
<p><span class="Bold Underline">For Subcutaneous Injection</span></p>
<p>The best sites for injection are areas on your body with a layer of fat between skin and muscle such as (See <a href="#FigureK_Injection">Figure K</a>):</p>
<ul>
<li>the front of your middle thighs</li>
<li>the outer area of your upper arms</li>
<li>the abdomen, except around your belly button (navel)<div class="Figure">
<a name="FigureK_Injection"></a><img alt="Figure K" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-11.jpg"><p class="MultiMediaCaption">Figure K</p>
</div>
</li>
</ul>
<p><span class="Bold Underline">For Intramuscular Injection</span></p>
<p>The best sites for injection into your muscle are (See <a href="#FigureL_Injection">Figure L</a>):</p>
<ul>
<li>the front of your middle thighs </li>
<li>your upper arms </li>
<li>the upper outer areas of your buttocks<div class="Figure">
<a name="FigureL_Injection"></a><img alt="Figure L" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-12.jpg"><p class="MultiMediaCaption">Figure L</p>
</div>
</li>
</ul>
<p>You should use a different site each time you inject INTRON<span class="Bold"><span class="Sup">®</span></span> A to avoid soreness at any one site. Do not inject INTRON A into an area where the skin is irritated, red, bruised, infected or has <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>, stretch marks or lumps.</p>
<p><span class="Bold">How should I inject a dose of INTRON<span class="Sup">®</span> A?</span></p>
<dl>
<dt>15.</dt>
<dd>Clean the injection site with a new alcohol swab. Wait for the area to dry. </dd>
<dt>16.</dt>
<dd>Pick up the vial and syringe from your flat work surface. Remove the syringe and needle from the vial.  							<ul class="Circle">
<li>Hold the syringe in the hand that you will use to inject INTRON A. </li>
<li>Do not touch the needle or allow it to touch the work surface. </li>
</ul>
</dd>
<dt>17.</dt>
<dd>With your other hand, pinch a fold of the skin at the cleaned injection site.</dd>
</dl>
<p><span class="Bold">For subcutaneous injection (under the skin):</span></p>
<ul class="Circle"><li>Hold the syringe (like a pencil) at a <span class="Bold">45-degree angle</span> to the skin. With a quick "dart-like" motion, push the needle into the skin (See <a href="#FigureM_Injection">Figure M</a>). 							<div class="Figure">
<a name="FigureM_Injection"></a><img alt="Figure M" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-13.jpg"><p class="MultiMediaCaption">Figure M</p>
</div>
</li></ul>
<p><span class="Bold">For intramuscular injection (into the muscle):</span></p>
<ul class="Circle"><li>Hold the syringe (like a pencil) at a <span class="Bold">90-degree angle</span> to the skin. With a quick "dart-like" motion, push the needle into the muscle (See <a href="#FigureN_Injection">Figure N</a>).<div class="Figure">
<a name="FigureN_Injection"></a><img alt="Figure N" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-14.jpg"><p class="MultiMediaCaption">Figure N</p>
</div>
</li></ul>
<dl>
<dt>18.</dt>
<dd>After the needle is inserted, remove the hand used to pinch the skin. Use it to hold the syringe barrel.<ul class="Circle">
<li>Pull the plunger back slightly. </li>
<li>
<span class="Bold">If no blood is present in the syringe,</span> inject the medicine by gently pressing the plunger all the way down the syringe barrel, until the syringe is empty.</li>
<li>
<span class="Bold">If blood comes into the syringe,</span> the needle has entered a blood vessel. Do not inject INTRON<span class="Bold"><span class="Sup">®</span></span> A.<ul class="Circle">
<li>Withdraw the needle and dispose of the syringe and needle in the sharps disposal container. See "<a href="#How_should_I_dispose">How should I dispose of used syringes, needles and vials?</a>" at the end of this Instructions for Use</li>
<li>If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, cover the injection site with a bandage.</li>
<li>Then, repeat steps 1 through 18 with a new dose of INTRON A and inject the medicine at a new injection site.</li>
</ul>
</li>
</ul>
</dd>
</dl>
<dl>
<dt>19.</dt>
<dd>When the syringe is empty, pull the needle out of the skin. 							<ul class="Circle">
<li>Place a cotton ball or gauze over the injection site and press for several seconds. Do not massage the injection site. </li>
<li>If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, cover the injection site with a bandage.</li>
</ul>
</dd>
<dt>20.</dt>
<dd>Dispose of used syringes, needles and vials in the sharps disposal container. See "<a href="#How_should_I_dispose">How should I dispose of used syringes, needles, and vials?</a>" below.</dd>
</dl>
<p><a name="How_should_I_dispose"></a><span class="Bold">How should I dispose of used syringes, needles, and vials?</span></p>
<ul>
<li>Put your used needles, syringes and vials in a FDA-cleared sharps disposal container right away after use. <span class="Bold">Do not throw away (dispose of) loose needles, syringes and vials in your household trash.</span>
</li>
<li>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:<ul class="Circle">
<li>made of a heavy-duty plastic,</li>
<li>closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</li>
<li>upright and stable during use,</li>
<li>leak-resistant, and</li>
<li>properly labeled to warn of hazardous waste inside the container.</li>
</ul>
</li>
<li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container.  There may be state or local laws about how you should throw away used syringes and needles.  For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</li>
<li>Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.</li>
<li>Always keep the sharps disposal container out of the reach of children.</li>
</ul>
<p><span class="Bold">How should I store INTRON<span class="Sup">®</span> A?</span></p>
<ul>
<li>Store in the refrigerator at 36°F to 46°F (2°C to 8°C).</li>
<li>Do not freeze Intron A.</li>
<li>Allow the INTRON A Solution for Injection to come to room temperature before using. INTRON A Solution in Multidose vials for Injection may be used to give more than 1 injection of medicine.</li>
<li>Throw away any unused INTRON A Solution for Injection remaining in the vial after 1 month</li>
<li>Keep away from heat.</li>
<li><span class="Bold">Keep INTRON A and all medicines out of the reach of children.</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<p class="First">Schering Corporation, a subsidiary of  <span class="Bold">MERCK &amp; CO. INC.,</span> Whitehouse Station, NJ 08889 USA </p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 1996, 2011, Schering Corporation, a subsidiary of <span class="Bold">Merck &amp; Co. Inc.</span><br>All rights reserved.</p>
<p>Rev. 08/2014</p>
<p>usifu-mk2958-soi-1408r006</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ifu-powder"></a><a name="section-19"></a><p></p>
<h1>Instructions for Use</h1>
<p class="First"><span class="Bold">INTRON<span class="Sup">®</span> A</span> (In-tron-aye)<br><span class="Bold">(Interferon alfa-2b, recombinant)<br> Powder for Solution</span></p>
<p>Be sure that you read, understand, and follow these instructions before injecting INTRON A. Your healthcare provider should show you how to prepare, measure, and inject INTRON A properly before you use it for the first time. Ask your healthcare provider if you have any questions.</p>
<p>Before starting, collect all of the supplies that you will need to use for preparing and injecting INTRON A. For each injection you will need the following supplies:</p>
<ul class="Circle">
<li>1 vial of INTRON A powder for solution</li>
<li>1 vial of sterile water for injection (diluent). The vial contains an excess amount of sterile water (5 mL). You will only need to withdraw 1 mL to prepare your single dose.</li>
<li>1 single-use disposable syringe and needle</li>
<li>1 cotton ball or gauze </li>
<li>2 alcohol swabs </li>
<li>1 sharps disposal container for throwing away (dispose of) your used syringes, needles, and vials. See "<a href="#How_should_I_dispose_Powder">How should I dispose of used syringes, needles, and vials?</a>" at the end of this Instructions for Use.</li>
</ul>
<p><span class="Bold">Important:</span></p>
<ul class="Circle">
<li><span class="Bold">Never re-use disposable syringes and needles.</span></li>
<li>The vial of mixed INTRON A should be used right away. Do not mix more than 1 vial of INTRON A at a time. If you do not use the vial of prepared solution right away, store it in a refrigerator and use within 24 hours. See the end of this Instructions for Use for information about "<a href="#How_should_I_store">How should I store INTRON A?</a>"</li>
<li>After mixing, throw away (discard) the vial of INTRON A after you withdraw one dose of medicine. </li>
<li>Make sure you have the right syringe and needle to use with INTRON A. Your healthcare provider should tell you what syringes and needles to use to inject INTRON A. </li>
</ul>
<p><span class="Bold">How should I prepare a dose of INTRON A?</span></p>
<p>Before you inject INTRON A, the powder must be mixed with 1 mL (cc) of the sterile water for injection (diluent) from the INTRON A vial package.</p>
<dl>
<dt>1.</dt>
<dd>Find a clean, well-lit, flat work surface. </dd>
<dt>2.</dt>
<dd>Get one of your INTRON A vial packages. Check the date printed on the carton. Make sure that the expiration date has not passed. </dd>
<dt>3.</dt>
<dd>Wash your hands well with soap and water. Keep your work area, your hands, and injection site clean to decrease the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (See <a href="#FigureA_Powder">Figure A</a>).<div class="Figure">
<a name="FigureA_Powder"></a><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-15.jpg"><p class="MultiMediaCaption">Figure A</p>
</div>
</dd>
<dt>4.</dt>
<dd>Gently warm the vial of diluent by slowly rolling the vial in the palms of your hands for one minute (See <a href="#FigureB_Powder">Figure B</a>).<div class="Figure">
<a name="FigureB_Powder"></a><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-04.jpg"><p class="MultiMediaCaption">Figure B</p>
</div>
</dd>
<dt>5.</dt>
<dd>Remove the protective plastic cap from the tops of both vials (INTRON A powder and the diluent). Clean the rubber stopper on the top of both vials with an alcohol swab (See <a href="#FigureC_Powder">Figure C</a>).<div class="Figure">
<a name="FigureC_Powder"></a><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-16.jpg"><p class="MultiMediaCaption">Figure C</p>
</div>
</dd>
<dt>6.</dt>
<dd>Open the package for the syringe (See <a href="#FigureD_Powder">Figure D</a>) you are using and if it does not have a needle attached, then attach a new needle to the syringe.<div class="Figure">
<a name="FigureD_Powder"></a><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-05.jpg"><p class="MultiMediaCaption">Figure D</p>
</div>
</dd>
<dt>7.</dt>
<dd>Remove the needle cover from the syringe. Fill the syringe with air by pulling the plunger back to 1 mL (See <a href="#FigureE_Powder">Figure E</a>). <div class="Figure">
<a name="FigureE_Powder"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-06.jpg"><p class="MultiMediaCaption">Figure E</p>
</div>
</dd>
<dt>8.</dt>
<dd>Hold the diluent vial on your flat work surface. Do not touch the cleaned rubber stopper (See <a href="#FigureF_Powder">Figure F</a>).<div class="Figure">
<a name="FigureF_Powder"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-07.jpg"><p class="MultiMediaCaption">Figure F</p>
</div>
</dd>
<dt>9.</dt>
<dd>Push the needle straight down through the middle of the rubber stopper of the diluent vial and slowly inject all the air from the syringe into the air space above the diluent (See <a href="#FigureG_Powder">Figure G</a>).<div class="Figure">
<a name="FigureG_Powder"></a><img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-08.jpg"><p class="MultiMediaCaption">Figure G</p>
</div>
</dd>
<dt>10.</dt>
<dd>Keep the needle in the vial. Turn the vial upside down and make sure the tip of the needle is in the diluent. 							<ul class="Circle">
<li>Important: The sterile water for injection vial contains an excess amount of sterile water (5 mL). <span class="Bold">You will only need to withdraw 1 mL to prepare your single dose.</span>
</li>
<li>Slowly pull the plunger back to fill the syringe with diluent to the <span class="Bold">1 mL mark</span> on the side of the syringe (See <a href="#FigureH_Powder">Figure H</a>).<div class="Figure">
<a name="FigureH_Powder"></a><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-09.jpg"><p class="MultiMediaCaption">Figure H</p>
</div>
</li>
</ul>
</dd>
<dt>11.</dt>
<dd>With the needle still inserted in the vial, check the syringe for air bubbles (See <a href="#FigureI_Powder">Figure I</a>). 							<ul class="Circle">
<li>If there are any air bubbles, gently tap the syringe with your finger until the air bubbles rise to the top of the syringe. </li>
<li>Slowly push the plunger up to remove the air bubbles. </li>
</ul>
</dd>
<dt> </dt>
<dd>If you push diluent back into the vial, slowly pull back on the plunger to again draw 1 mL of diluent back into the syringe.<div class="Figure">
<a name="FigureI_Powder"></a><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-10.jpg"><p class="MultiMediaCaption">Figure I</p>
</div>
</dd>
<dt>12.</dt>
<dd>Remove the needle from the vial. Do not let the syringe touch anything.</dd>
<dt>13.</dt>
<dd>Throw away the diluent that is left over in the vial. <span class="Bold">Do not save any leftover diluent or use it again.</span> See "<a href="#How_should_I_dispose_Powder">How should I dispose of used syringes, needles, and vials</a>" at the end of this Instructions for Use.</dd>
<dt>14.</dt>
<dd>Insert the needle through the center of the rubber stopper of the INTRON A powder vial. Do not touch the cleaned rubber stopper.<ul class="Circle">
<li>Place the needle tip, at an angle, against the side of the INTRON A powder vial (See <a href="#FigureJ_Powder">Figure J</a>).<div class="Figure">
<a name="FigureJ_Powder"></a><img alt="Figure J" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-17.jpg"><p class="MultiMediaCaption">Figure J</p>
</div>
</li>
<li>Slowly push the plunger down to inject the diluent into the vial. The stream of liquid should run down the sides of the glass vial. </li>
<li>To prevent bubbles from forming, do not aim the stream of diluent directly on the medicine in the bottom of the vial.</li>
<li>Do not remove the needle from the vial. </li>
</ul>
</dd>
<dt>15.</dt>
<dd>Gently swirl the INTRON A vial in a circular motion until the powder is completely dissolved (See <a href="#FigureK_Powder">Figure K</a>).<div class="Figure">
<a name="FigureK_Powder"></a><img alt="Figure K" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-18.jpg"><p class="MultiMediaCaption">Figure K</p>
</div>
<ul class="Circle">
<li>Do not shake the vial. If any powder remains undissolved in the vial, gently turn the vial upside down until all of the powder is dissolved.</li>
<li>The solution may look cloudy or bubbly for a few minutes. If air bubbles do form, wait until the solution settles and all bubbles rise to the top. Then withdraw your dose from the vial.</li>
</ul>
</dd>
<dt>16.</dt>
<dd>After the INTRON A completely dissolves, the solution should be clear and colorless to light yellow, without particles. Do not use the mixed solution if you see particles in it, or it is not clear and colorless to light yellow. </dd>
<dt>17.</dt>
<dd>With the needle in the vial, turn the vial upside down (See <a href="#FigureL_Powder">Figure L</a>).<div class="Figure">
<a name="FigureL_Powder"></a><img alt="Figure L" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-19.jpg"><p class="MultiMediaCaption">Figure L</p>
</div>
<ul class="Circle"><li>Hold the vial with one hand. Be sure the tip of the needle is in the INTRON A solution. Slowly pull the plunger back to fill the syringe with the exact amount of INTRON A into the syringe that your healthcare provider told you to use.</li></ul>
</dd>
<dt>18.</dt>
<dd>With the needle still inserted in the vial, check the syringe for air bubbles. If you see any air bubbles, gently tap the syringe with your finger until the air bubbles rise to the top of the syringe (See <a href="#FigureM_Powder">Figure M</a>).<div class="Figure">
<a name="FigureM_Powder"></a><img alt="Figure M" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-20.jpg"><p class="MultiMediaCaption">Figure M</p>
</div>
</dd>
<dt>19.</dt>
<dd>Slowly push the plunger up to remove the air bubbles. If you push solution back into the vial, slowly pull back on the plunger again to draw the correct amount of INTRON A solution back into the syringe. </dd>
<dt>20.</dt>
<dd>Do not remove the needle from the vial. Lay the vial and syringe on its side on your flat work surface until you are ready to inject the INTRON A solution.</dd>
</dl>
<p><span class="Bold">How should I choose a site for injection?</span></p>
<p>Based on your treatment, your healthcare provider will tell you if you should inject a dose of INTRON<span class="Bold"><span class="Sup">®</span></span> A under the skin (subcutaneous injection) or into the muscle (intramuscular injection). If it is too difficult for you to inject, ask someone who has been trained to give injections to help you.</p>
<p><span class="Bold Underline">For Subcutaneous Injection</span></p>
<p>The best sites for injection are areas on your body with a layer of fat between skin and muscle, such as (See <a href="#FigureN_Powder">Figure N</a>):</p>
<ul>
<li>the front of your middle thighs </li>
<li>the outer area of your upper arms </li>
<li>the abdomen, except around your belly-button (navel)<div class="Figure">
<a name="FigureN_Powder"></a><img alt="Figure N" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-11.jpg"><p class="MultiMediaCaption">Figure N</p>
</div>
</li>
</ul>
<p><span class="Bold Underline">For Intramuscular Injection</span></p>
<p>The best sites for injection into your muscle are (See <a href="#FigureO_Powder">Figure O</a>):</p>
<ul>
<li>the front of your middle thighs </li>
<li>your upper arms </li>
<li>the upper outer areas of your buttocks<div class="Figure">
<a name="FigureO_Powder"></a><img alt="Figure O" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-12.jpg"><p class="MultiMediaCaption">Figure O</p>
</div>
</li>
</ul>
<p>You should use a different site each time you inject INTRON<span class="Bold"><span class="Sup">®</span></span> A to avoid soreness at any one site. Do not inject INTRON A into an area where the skin is irritated, red, bruised, infected or has <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>, stretch marks, or lumps.</p>
<p><span class="Bold">How should I inject a dose of INTRON<span class="Sup">®</span> A?</span></p>
<dl>
<dt>21.</dt>
<dd>Clean the injection site with a new alcohol swab. Wait for the skin to dry. </dd>
<dt>22.</dt>
<dd>Pick up the vial and syringe from your flat work surface. Remove the syringe and needle from the vial. 							<ul class="Circle">
<li>Hold the syringe in the hand that you will use to inject INTRON A. </li>
<li>Do not touch the needle or allow it to touch the work surface. </li>
</ul>
</dd>
<dt>23.</dt>
<dd>With one hand, pinch a fold of the skin at the cleaned injection site. </dd>
<dt>24.</dt>
<dd>
<span class="Bold">For subcutaneous injection (under the skin):</span><ul class="Circle"><li>With the other hand, hold the syringe (like a pencil) at a <span class="Bold">45-degree angle</span> to the skin. With a quick "dart-like" motion, push the needle into the skin (See <a href="#FigureP_Powder">Figure P</a>).<div class="Figure">
<a name="FigureP_Powder"></a><img alt="Figure P" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-13.jpg"><p class="MultiMediaCaption">Figure P</p>
</div>
</li></ul>
</dd>
<dt>25.</dt>
<dd>
<span class="Bold">For intramuscular injection (into the muscle):</span><ul class="Circle">
<li>Hold the syringe (like a pencil) at a <span class="Bold">90-degree angle</span> to the skin. </li>
<li>With a quick "dart-like" motion, push the needle into the muscle (See <a href="#FigureQ_Powder">Figure Q</a>).<div class="Figure">
<a name="FigureQ_Powder"></a><img alt="Figure Q" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-14.jpg"><p class="MultiMediaCaption">Figure Q</p>
</div>
</li>
</ul>
</dd>
<dt>26.</dt>
<dd>After the needle is inserted, remove the hand used to pinch the skin and use it to hold the syringe barrel. 							<ul class="Circle">
<li>Pull the plunger back slightly. </li>
<li>
<span class="Bold">If no blood is present in the syringe</span>, inject the medicine by gently pushing the plunger all the way down the syringe barrel, until the syringe is empty.</li>
<li>
<span class="Bold">If blood comes into the syringe</span>, the needle has entered a blood vessel. Do not inject INTRON<span class="Bold"><span class="Sup">®</span></span> A.<ul class="Circle">
<li>Withdraw the needle and dispose of the syringe and needle in the sharps disposal container<span class="Italics">.</span> See section "<a href="#How_should_I_dispose_Powder">How should I dispose of used syringes, needles, and vials?</a>" at the end of this Instructions for Use.</li>
<li>If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, cover the injection site with a bandage.</li>
<li>Then, repeat steps 1 through 25 with a new dose of INTRON A and inject the medicine at a new injection site.</li>
</ul>
</li>
</ul>
</dd>
<dt>27.</dt>
<dd>When the syringe is empty, pull the needle out of the skin.  							<ul class="Circle">
<li>Place a cotton ball or gauze over the injection site and press for several seconds. Do not massage the injection site. </li>
<li>If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, cover the injection site with a bandage. </li>
</ul>
</dd>
<dt>28.</dt>
<dd>Dispose of used syringes, needles, and vials in the sharps disposal container. (See "<a href="#How_should_I_dispose_Powder">How should I dispose of used syringes, needles, and vials?</a>" below.)</dd>
</dl>
<p><a name="How_should_I_dispose_Powder"></a><span class="Bold">How should I dispose of used syringes, needles, and vials?</span></p>
<ul class="Disc">
<li>Put your used needles, syringes and vials in a FDA-cleared sharps disposal container right away after use. <span class="Bold">Do not throw away (dispose of) loose needles, syringes and vials in your household trash.</span>
</li>
<li>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:<ul class="Circle">
<li>made of a heavy-duty plastic,</li>
<li>closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</li>
<li>upright and stable during use,</li>
<li>leak-resistant, and</li>
<li>properly labeled to warn of hazardous waste inside the container.</li>
</ul>
</li>
<li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container.  There may be state or local laws about how you should throw away used syringes and needles.  For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</li>
<li>Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container. 							</li>
</ul>
<p>Always keep the sharps disposal container out of the reach of children.</p>
<p><a name="How_should_I_store"></a><span class="Bold">How should I store INTRON<span class="Sup">®</span> A?</span></p>
<ul class="Disc">
<li>Before mixing, store in the refrigerator between 36°F to 46°F (2°C to 8°C).</li>
<li>After mixing the INTRON A Powder for Injection, use the solution right away or store the solution in the refrigerator for up to 24 hours between 36°F to 46°F (2°C to 8°C). Allow the solution to come to room temperature before using.</li>
<li>Do not freeze Intron A.</li>
<li>Keep away from heat.</li>
<li>Throw away any medicine left in the vial after you withdraw 1 dose.</li>
</ul>
<p><span class="Bold">Keep INTRON A and all medicines out of the reach of children.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-20"></a><p></p>
<p class="First">This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by:<br>Schering Corporation, a subsidiary of <span class="Bold"> MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889 USA</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 1996, 2011, Schering Corporation, a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>Revised: 08/2014</p>
<p>usifu-mk2958-pwi-5ml-1408r000</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 Million IU Single-Use Vial Kit Carton</h1>
<p class="First"><span class="Bold">SCHERING</span></p>
<p><span class="Bold">NDC</span> 0085-4350-01<br><span class="Bold">Refrigerate</span></p>
<p><span class="Bold">Interferon alfa-2b,<br>recombinant</span></p>
<p><span class="Bold">Intron<span class="Sup">®</span> A<br>Powder for Injection<br>Single-Use Vial</span></p>
<p><span class="Bold">10 million IU per vial</span></p>
<p><span class="Bold">For Intramuscular/Subcutaneous/Intravenous/<br>Intralesional Use.</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Medication Guide for patient enclosed.<br><span class="Bold">Dosage and Administration:</span><br>See package insert.<br>Reconstitute as directed in package insert.<br>Read accompanying directions.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 Million IU Single-Use Vial Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-21.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 18 Million IU Single-Use Vial Kit Carton</h1>
<p class="First"><span class="Bold">NDC</span> 0085-4351-01<br><span class="Bold">Refrigerate</span></p>
<p><span class="Bold">(Interferon alfa-2b, recombinant)<br>Intron<span class="Sup">®</span> A<br>Powder for Injection<br>Single-Use Vial</span></p>
<p><span class="Bold">18 million IU per vial</span></p>
<p>For Intramuscular/Subcutaneous/<br>Intravenous Use<br>NOT FOR INTRALESIONAL USE.</p>
<p><span class="Bold">INTRON</span><span class="Sup">®</span><span class="Bold"> A</span><br>Intereferon Alfa-<span class="Bold">2b</span>, Recombinant<br>for Injection</p>
<p><span class="Bold">Rx only</span><br>Medication Guide for patient enclosed.<br><span class="Bold">Dosage and Administration:</span> See package insert.<br>Read accompanying directions.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 18 Million IU Single-Use Vial Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-22.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 Million IU Single-Use Vial Kit Carton</h1>
<p class="First"><span class="Bold">NDC</span> 0085-4352-01<br><span class="Bold">Refrigerate</span></p>
<p><span class="Bold">(Interferon alfa-2b, recombinant)<br>Intron<span class="Sup">®</span> A<br>Powder for Injection<br>Single-Use Vial</span></p>
<p><span class="Bold">50 million IU per vial</span></p>
<p>For Intramuscular/Subcutaneous/<br>Intravenous Use<br>NOT FOR INTRALESIONAL USE.</p>
<p><span class="Bold">INTRON</span><span class="Sup">®</span><span class="Bold"> A</span><br>Intereferon Alfa-<span class="Bold">2b</span>, Recombinant<br>for Injection</p>
<p><span class="Bold">Rx only</span><br>Medication Guide for patient enclosed.<br><span class="Bold">Dosage and Administration:</span> See package insert.<br>Read accompanying directions.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 Million IU Single-Use Vial Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-23.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-24"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 18 Million IU Multidose Vial Kit Carton</h1>
<p class="First"><span class="Bold">NDC</span> 0085-1168-01<br><span class="Bold">Refrigerate</span></p>
<p><span class="Bold">(Interferon alfa-2b, recombinant)<br>Intron<span class="Sup">®</span> A<br>Solution for Injection</span></p>
<p><span class="Bold">18 million IU multidose vial<br>3 million IU/0.5 mL</span></p>
<p>For Intramuscular/Subcutaneous Use.<br>NOT FOR INTRALESIONAL USE.</p>
<p><span class="Bold">INTRON</span><span class="Sup">®</span><span class="Bold"> A</span><br>Intereferon Alfa-<span class="Bold">2b</span>, Recombinant<br>for Injection</p>
<p><span class="Bold">Rx only</span><br>Medication Guide for patient enclosed.<br><span class="Bold">Dosage and Administration:</span> See package insert.<br>Read accompanying directions.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 18 Million IU Multidose Vial Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-24.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-25"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 25 Million IU Multidose Vial Kit Carton</h1>
<p class="First"><span class="Bold">NDC</span> 0085-1133-01<br><span class="Bold">Refrigerate</span></p>
<p><span class="Bold">(Interferon alfa-2b, recombinant)<br>Intron<span class="Sup">®</span> A<br>Solution for Injection</span></p>
<p><span class="Bold">25 million IU multidose vial<br>5 million IU/0.5 mL</span></p>
<p>For Intramuscular/Subcutaneous/<br>Intralesional Use</p>
<p><span class="Bold">INTRON</span><span class="Sup">®</span><span class="Bold"> A</span><br>Intereferon Alfa-<span class="Bold">2b</span>, Recombinant<br>for Injection</p>
<p><span class="Bold">Rx only</span><br>Medication Guide for patient enclosed.<br><span class="Bold">Dosage and Administration:</span> See package insert.<br>Read accompanying directions.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 25 Million IU Multidose Vial Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30789790-8317-49f9-b97b-8c5ba17b53d2&amp;name=intron-5ml-25.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTRON A 		
					</strong><br><span class="contentTableReg">interferon alfa-2b kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-4350</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-4350-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">1.25 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>INTRON A 		
					</strong><br><span class="contentTableReg">interferon alfa-2b injection, powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRALESIONAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>interferon alfa-2b</strong> (interferon alfa-2b) </td>
<td class="formItem">interferon alfa-2b</td>
<td class="formItem">38 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glycine</strong></td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Phosphate, Dibasic</strong></td>
<td class="formItem">2.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Phosphate, Monobasic</strong></td>
<td class="formItem">0.55 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Albumin (Human)</strong></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.25 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">06/04/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-4346</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRALESIONAL, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-4346-01</td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">08/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">08/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTRON A 		
					</strong><br><span class="contentTableReg">interferon alfa-2b kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-4351</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-4351-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">1.25 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>INTRON A 		
					</strong><br><span class="contentTableReg">interferon alfa-2b injection, powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>interferon alfa-2b</strong> (interferon alfa-2b) </td>
<td class="formItem">interferon alfa-2b</td>
<td class="formItem">69 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glycine</strong></td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Phosphate, Dibasic</strong></td>
<td class="formItem">2.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Phosphate, Monobasic</strong></td>
<td class="formItem">0.55 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Albumin (Human)</strong></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.25 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">06/04/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-4346</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-4346-01</td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">08/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">08/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTRON A 		
					</strong><br><span class="contentTableReg">interferon alfa-2b kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-4352</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-4352-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">1.25 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>INTRON A 		
					</strong><br><span class="contentTableReg">interferon alfa-2b injection, powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>interferon alfa-2b</strong> (interferon alfa-2b) </td>
<td class="formItem">interferon alfa-2b</td>
<td class="formItem">192 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glycine</strong></td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Phosphate, Dibasic</strong></td>
<td class="formItem">2.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Phosphate, Monobasic</strong></td>
<td class="formItem">0.55 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Albumin (Human)</strong></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.25 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">06/04/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">water injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-4346</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-4346-01</td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">08/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">08/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTRON A 		
					</strong><br><span class="contentTableReg">interferon alfa-2b injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-1168</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Interferon alfa-2b</strong> (Interferon alfa-2b) </td>
<td class="formItem">Interferon alfa-2b</td>
<td class="formItem">11.6 ug  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">3.75 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem">0.9 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem">0.65 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem">0.05 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">0.05 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>metacresol</strong></td>
<td class="formItem">0.75 mg  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-1168-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.8 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">06/04/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INTRON A 		
					</strong><br><span class="contentTableReg">interferon alfa-2b injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0085-1133</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAMUSCULAR, INTRALESIONAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Interferon alfa-2b</strong> (Interferon alfa-2b) </td>
<td class="formItem">Interferon alfa-2b</td>
<td class="formItem">19.2 ug  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">3.75 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem">0.9 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem">0.65 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem">0.05 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">0.05 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>metacresol</strong></td>
<td class="formItem">0.75 mg  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0085-1133-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.2 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103132</td>
<td class="formItem">06/04/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merck Sharp &amp; Dohme Corp.
							(001317601)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Schering-Plough (Ireland) Company</td>
<td class="formItem"></td>
<td class="formItem">986118438</td>
<td class="formItem">MANUFACTURE(0085-1168, 0085-1133, 0085-4350, 0085-4351, 0085-4352), API MANUFACTURE(0085-1168, 0085-1133, 0085-4350, 0085-4351, 0085-4352)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Jubilant HollisterStier LLC</td>
<td class="formItem"></td>
<td class="formItem">069263643</td>
<td class="formItem">MANUFACTURE(0085-1168, 0085-1133)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">001728059</td>
<td class="formItem">MANUFACTURE(0085-4350, 0085-4351, 0085-4352, 0085-4346)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a9acbb0a-5c41-4bc4-a158-c2c911e0f30a</div>
<div>Set id: 30789790-8317-49f9-b97b-8c5ba17b53d2</div>
<div>Version: 3</div>
<div>Effective Time: 20150521</div>
</div>
</div> <div class="DistributorName">Merck Sharp &amp; Dohme Corp.</div></p>
</body></html>
